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I. INTRODUCTION 
Description and, more exactly, the recognition and subsequent proper evaluation 
of pain are very difficult. Pain is a universal and subjective unpleasant experience 
commonly associated with tissue-damaging stimuli. It is a sensitive stimulation of 
individual origin which is difficult to evaluate in animals, because of the lack of 
objective systems to recognize this experience (AIGÉ AND CRUZ, 2001; 
WATERMAN-PEARSON, 2001). People can verbally express their feelings 
whereas the evaluation of nociception in animals requires dedication and 
understanding of the different behavioural and physiological changes that an 
animal will present.  The observation of evident signs and their correct 
interpretation are necessary to recognize the experience of pain 
(HELLEBRECKERS 2002, STASIAK et al. 2003). In the past animals were 
considered to have an inferior level of development than human beings and 
consequently it was believed that they could not feel pain in the same way as 
humans. Nonetheless it has been observed that animals respond with violent 
movements, vocalisations and aversive behaviours when hurt 
(HELLEBRECKERS 2002, WATERMAN-PEARSON 2001).  
The ability to feel pain has an advantage in survival because it limits the extension 
of the injury, provokes rest and wound healing, assuring that the animal learns to 
avoid noxious stimuli. In other terms it is an alarm sign essential to survival or a 
protective reflex, whose purpose is withdrawal of the damaged tissue away from 
potentially noxious stimuli. However, continuous pain sensation induces stress 
that, when severe, may threaten the animal’s well-being (CAILLIET 1995, 
WATERMAN-PEARSON 2001). Many veterinary practitioners do not feel the 
necessity to treat their patients for pain, because they conclude that an animal 
walking and eating normally cannot be suffering from pain and therefore does not 
need analgesics (GAYNOR 1999).  
The lack of attention to pain therapy is mainly due to a tendency to misinterpret 
the external signs of pain as well as due to a lack of appreciation for the 
importance of it (GARCÍA and YNARAJA 1999). Today it is recognized that 
control and treatment of pain is an essential part of a professional and 
conscientious handling of animals (AIGÉ AND CRUZ 2001).  
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II. LITERATURE 
1. Physiology of pain 
1.1. Definition of pain 
It is prudent to differentiate the term pain from nociception. The International 
Association for the Study of Pain (IASP) defines pain as ‘a sensorial or unpleasant 
emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage’ (HELLEBRECKERS, 2002; HELLYER 
2007). This definition incorporates a psychological component, which can alter 
pain perception (MELLO and DICKENSON, 2008). The sensation of pain is well 
known in humans, because it can be verbally defined. Animals, conversely, 
cannot verbally express their feelings making it impossible to know if they feel 
pain as described by humans (DEGENAAR, 1979). However, the inability to 
communicate does not negate the possibility that an individual is experiencing 
pain and, moreover, noxious stimuli in animals elicit reflex withdrawal, 
behavioural, neuroendocrine and autonomic nervous system responses 
comparable to humans (MUIR and WOOLF, 2001). The term nociception is 
related to the recognition of the noxious stimulus in the central nervous system 
that originates in sensitive receptors providing the information related to the 
damaged tissue (HELLEBRECKERS, 2002; LEMKE, 2004).  
1.2. Nociception 
Nociception can be defined as the transduction, transmission, modulation and 
central nervous system processing of the signals produced upon stimulation of 
specific receptors. It is the physiological process that, once finished, produces the 
conscious perception of pain (TRANQUILLI et al., 2001; LEMKE, 2004). 
Transmission occurs through a three-neuron chain (fig. 1). A noxious stimulus in 
the periphery activates a primary afferent fibre that transmits the information to 
the dorsal horn of the spinal cord. Here, a second order projection neuron that 
ascends in a spinal tract to the level of the thalamus intervenes. Finally, a tertiaty 
neuron transmits the modified noxious stimulus to higher brain centers, notably 
the cerebral cortex, for perception (LEMKE, 2004). 
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Figure 1: A simplified representation of nociceptive processing as a three-
neuron chain (LEMKE et al. 2004). 
 
1.2.1. Peripheral receptors  
The transduction is the appreciation of different types of inciting stimuli. It is the 
encoding through peripheral receptors of familiar sensations such as temperature, 
touch and pain (mechanical, chemical, or thermal energy) into electric impulses. 
These receptors in the skin can be further classified according to sensory 
modality. For example, thermoreceptors respond to warming or cooling of the 
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skin, whereas mechanoreceptors respond to pressure, stretch or hair movement. In 
addition to these neurons that respond to innocuous touch and temperature, 
sensory neurons known as nociceptors initiate painful sensations. Many 
nociceptors are polymodal neurons that are activated by various types of sensory 
stimuli (LAMONT et al., 2000, LUMPKIN and CATERINA, 2007). Polymodal 
receptors respond to both mechanical and thermal or chemical stimuli. Chemical 
stimuli are substances liberated in damaged tissues like bradykinin (main cause of 
pain), serotonin, histamine, potassium ions, acids (lactic acid in case of ischemia), 
acetylcholine, proteolytic enzymes and prostaglandins (PGs) (LEMKE, 2004).  
The sensitivity of nociceptors to sensory stimulation can be altered by signalling 
pathways engaged during injury or inflammation (LUMPKIN and CATERINA, 
2007).  
1.2.2. Afferent nerve fibres  
Following the transduction, the transmission of the pain stimulus takes place. The 
impulse is projected along the first-order neuron from the periphery to the dorsal 
horn of the spinal cord. Nociceptors are present in the nerve endings of about 70% 
of all peripheral nerve fibres (TORREGROSA, 1994; CAILLIET, 1995; 
LAMONT et al., 2000). In the case of mechanical and thermal receptors the first-
order neurons correspond to myelinated afferent Aδ fibres of small diameter that 
carry high-speed stimuli (5-30 m/s). These Aδ fibres are responsible for the “first 
acute pain”, which is often described as a sharp, stinging, or pricking sensation 
(fig.2).  Aδ fibres are activated, for example, during the withdrawal reflex. In this 
case a precise localization of the pain perception is possible. In contrast, if the 
stimulus is of sufficient magnitude, mechanoheat or polymodal receptors reinforce 
the response of the Aδ fibres through the activation of non-myelinated type C 
fibres of small diameter and low-speed nerve conduction velocity (0,5 – 2 m/s). 
These fibres are responsible for the “second” or “slow pain”, which is frequently 
diffuse, constant and persistent. Both Aδ and C fibres are located throughout the 
skin, peritoneum, pleura, periosteum, subchondral  bone, joint capsules, blood 
vessels, muscles, tendons, fascia, and viscera, although their distribution density 
varies depending on the species and anatomic location (LAMONT et al., 2000; 
MUIR and WOOLF, 2001). In the visceral tissue type C fibres respond to 
situations like ischemia, irritation and tension. They do not only transmit pain but 
also release vasodilator substances, generate neurogenic oedema and sensitize the 
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nerve terminals (GARCÍA and YNARAJA, 2001; LEMKE, 2004). Another type 
of afferent fibres are the large diameter and highly myelinated Aβ fibres, which 
quickly conduct action potentials from the periphery to central terminals. These 
fibres have low activation thresholds and normally respond to light touch. They 
are mainly responsible for conveying tactile non painful information (MELLO 
and DICKENSON, 2008). 
 
 Figure 2: Primary afferent pain transmission. First pain and second pain 
sensations after a noxious stimulus (A). The first pain sensation is abolished when 
the A fibres are blocked (B), while the second pain sensation is abolished when 
the C fibres are blocked (C) (LAMONT et al., 2000). 
 
1.2.3. Dorsal horn neurons  
All afferent nerve fibres enter the spinal cord through the dorsal root, where the 
processing and modulation of the signals takes place. Cell bodies of both types of 
afferent nerve fibres (Aδ and C) are located in the dorsal root ganglia and extend 
axons to synapse with second-order nociceptive neurons in the dorsal horn of the 
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spinal cord. On the spinal level there are three main types of nociceptive neurons: 
interneurons, propriospinal neurons and projecting neurons, all of which are 
organized in different laminae or layers. Neurons responsible for nociceptive 
mediation are located primarily in lamina I (marginal layer), lamina II (substantia 
gelatinosa), and lamina V. The majority of the Aδ fibres terminate in the most 
superficial layer with some fibres projecting more deeply to lamina V. Most C 
fibres send their axons to the superficial dorsal horn, with the focus in lamina II 
but also send a few branches to laminae I and V (LAMONT et al., 2000; MUIR 
AND WOOLF, 2001), whereas myelinated Aβ fibres innervate deeper laminae 
III-VI (MILLAN, 2002; MELLO and DICKENSON, 2008) (fig. 3). The deepest 
dorsal horn neurons also receive direct or indirect inputs from A-fibre nociceptors 
(HEINRICHER et al., 2009). 
The interneurons frequently are divided into excitatory (glutamatergic) and 
inhibitory (GABAergic) subtypes (MELLLO and DICKENSON, 2008), which 
serve as relays and participate in local processing. Propriospinal neurons extend 
over various spinal segments and are involved in segmental reflex activity and 
interactions among stimuli acting at separate places. Projection neurons are 
located in lamina I and V and participate in rostral transmission by extending 
axons beyond the spinal cord to supraspinal third-order neurons ending in 
supraspinal centres such as the midbrain and the cortex (LAMONT et al., 2000; 
LEMKE, 2004). 
Projection neurons have been also subclassified into two groups: (1) Nociceptive 
specific (NS) neurons are concentrated in lamina I and are excited solely by 
noxious mechanical or thermal input from both Aδ and C fibres. They are 
somatotopically arranged and respond to afferent impulses originating from 
discrete topographic areas. (2) Wide dynamic range neurons (WDR) predominate 
in lamina V and receive innocuous input from low-threshold mechanoreceptors 
(Aβ fibres) as well as nociceptive information (fig. 3). They respond in a graded 
manner over a larger receptive field than do NS neurons and often receive 
convergent deep and visceral input (LAMONT et al., 2000; MILLAN, 2002, 
MELLO AND DICKENSON, 2008). They constitute a strategic site where 
various types of excitatory and inhibitory influences converge (LE BARS, 2002). 
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Figure 3: Pain pathways from the periphery to the brain. Primary afferent 
fibres (Aβ-, Aδ-, and C-fibres) transmit impulses from the periphery, through the 
dorsal root ganglion (DRG) and into the dorsal horn of the spinal cord. 
Nociceptive specific (NS) cells are mainly found in the superficial dorsal horn 
(lamina I-II), whereas most wide dynamic range (WDR) neurons are located 
deeper in lamina V (MELLO and DICKENSON, 2008). 
 
The communication of nociceptive information occurs via chemical signalling 
mediated by excitatory and inhibitory amino acids and neuropeptides. Nociceptive 
Aδ and C fibres, as well as non-nociceptive fibres, co-release excitatory amino 
acids (glutamate and aspartate) and neuropeptides (substance P, neurokinin A, 
calcitonin gene-related peptide (CGRP) and cholecystokinin) that bind to distinct 
receptors on dorsal horn neurons, among which the α-amino-3-hydroxy 5-methyl-
4-isoxazelopropionic acid (AMPA) receptor and the N-methyl-D-aspartate 
(NMDA) receptor are of great significance (MUIR and WOOLF, 2001; MELLO 
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and DICKENSON, 2008). MILLAN (2002) also mentions the activation of 
tachykinin (NK) 1- (preferred ligand: substance P) and possibly NK2- (preferred 
ligand: neurokinin A) and NK3-receptors (preferred ligand: neurokinin B), which 
play an important role in nociceptive transmission. NK1 receptors are mostly 
distributed in lamina I (MORRIS et al., 2004). 
1.2.4. Ascending spinal tracts  
All nociceptive inputs are conveyed to supraspinal centres by projection neurons. 
A large population of these projection neurons is found superficially in laminae I 
and it is estimated that 80% of these cells express NK1 receptor for substance P. 
NK1-positive fibres project to areas in the brain such as the thalamus, the 
periaqueductal grey (PAG), and the parabrachial area (PB) (TODD, 2002). These 
projections are achieved through one of several pathways: the spinothalamic tract 
(STT) is one of the more important and prominent nociceptive pathways. It 
originates from the axons of NS and WDR neurons in laminae I, V, VI and VII 
which cross the midline and project to the thalamic nuclei and then via third order 
neurons to the limbic system and to the somatosensory cortex; it is responsible for 
the affective and emotional component involved in pain transmission and the 
sensory- discriminative aspects of pain sensation.  
Axons located more deeply in laminae VII and VIII form the spinoreticular tract 
that projects to the reticular formation in the medulla and pons, to thalamic nuclei 
and then to the somatosensory cortex. The reticular formation is crucial for the 
integration of nociceptive input. Ascending reticular activity increases cortical 
activity, while descending reticular activity blocks other sensory activity.  
Finally nociceptive neurons originating in laminae I and V project in the 
spinomesencephalic tract to the mesencephalic reticular formation, the lateral part 
of the periaqueductal gray matter (PAG), and several other midbrain sites. The 
PAG plays a central role in the integration and modulation of nociceptive input at 
the supraspinal levels (LAMONT et al., 2000; MUIR and WOOLF, 2001; 
LEMKE, 2004).  
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2. Pathophysiology of pain 
2.1. Causes of pain 
Independent of the quality (chemical, thermal or mechanical) of a noxious 
stimulus the peripheral nervous system transforms the stimulus energy into 
electrical energy for its subsequent recognition in the CNS (TRANQUILLI et al., 
2001). The visceral tissue, unlike the skin, is not highly sensitive to stimuli like 
pricking or the incision of a scalpel and normally this is not associated with 
intense pain, but it does respond to damaging processes like ischemia, spasm and 
overdistension (STOELTING AND HILLIER, 2006). Nociceptors present 
different activating thresholds depending basically on their localization (somatic 
or visceral). Upon tissue damage (cell destruction), potassium and several 
inflammatory mediators are released, including but not limited to PG, bradykinin, 
leukotriens, 5-hydroxytryptamine (5-HT), histamine, substance P, thromboxane, 
and platelet-activating factor. All of these neuroactive substances constitute a 
sensitizing soup that synergistically works to sensitize high-threshold nociceptors 
to mechanical, thermal, or chemical stimuli. The transmission of stimuli in the 
spinal cord is determined by, among others, the activation of spinal receptors 
which respond to substance P, glutamate or PG (WOOLF and CHONG, 1993; 
GARCÍA and YNARAJA, 1999; MUIR and WOOLF, 2001; VANEGAS and 
SCHAIBLE, 2001; LEMKE, 2004). PG released in the spinal cord enhances the 
production of glutamate and aspartate, both mediators then act pro-nociceptive at 
supraspinal levels (VANEGAS and SCHAIBLE, 2001; HEINRICHER et al., 
2004). On the other side, at supraspinal levels cyclooxygenase isoforms are 
tonically active in the PAG, too, and their products exert a facilitatory effect on 
acute spinal nociceptive processing, which preferentially targets C-nociceptors in 
the dorsal horn (LEITH et al. 2007). Involvement of nitric oxide (NO) in the 
mediation of pain has also been studied. The intracutaneous injection of NO 
evokes pain in humans (HOLTHUSEN and ARNDT, 1994).  Nitric oxide may 
also contribute to the transmission of excitatory impulses between primary 
afferents and secondary dorsal horn neurons (BUDAI et al., 1995). However, a 
pronociceptive activity of NO is controversial, since the antinociception produced 
by several analgesics is mediated through NO synthesis via the L-arginine-NO-
cGMP pathway (DUARTE et al., 1992; IWAMOTO and MARION, 1994; SONG 
et al., 1998; SACHS et al., 2003). 
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The incision of tissue produces injury and cell destruction, hence the liberation of 
several inflammatory mediators. These mediators are the main reason why a 
surgical process is potentially painful (MUIR and WOOLF, 2001). TRANQUILLI 
(1997) classified different surgical processes according to their ability to produce 
pain. This classification lists moderately painful mainly soft tissue surgical 
interventions, e.g. ovariohysterectomy, castration, and laparotomy, and severely 
painful interventions, e.g. thoracotomy or osteosynthesis.  
Although alloarthroplasty of the hip (total hip replacement) in dogs with 
coxarthrosis ensures a fast pain alleviation and total limb function after surgery 
(MATIS, 1995), the procedure includes soft tissue damage as well as bone 
dissection and therefore can be scored as a severely painful intervention, both 
intraoperatively and in the postoperative period (SCHEBITZ and BRASS, 1999).  
2.2. Types of pain  
According to the anatomical disposition of the nociceptive fibres and to their 
physiology, pain can be classified in two ways: somatic pain and visceral pain. 
Somatic tissues have more nociceptors and smaller receptive fields, while visceral 
tissues have fewer nociceptors and larger receptive fields (LAMONT et al., 2000). 
These anatomic differences may account for some of the qualitative differences 
between somatic (discrete) and visceral (diffuse) pain. Somatic pain can also be 
divided into superficial and deep pain. The superficial pain becomes evident when 
stimulating mechano- and heat receptors and is transmitted through Aδ fibres. 
Deep pain, conversely, is associated with the liberation of chemical substances 
which stimulate the nerve endings of type C fibres (TRANQUILLI et al., 2001, 
WATERMAN-PEARSON, 2001). Visceral pain is characterized by its difficulty 
to be localized and often it is referred to somatic areas. Here the sensations are 
carried through two different pathways: by a true visceral pathway or/and a 
parietal pathway. The parietal pathway is more specific, picks up sensations from 
body cavity walls and is formed by somatic fibres that are part of the spinal 
nerves. The visceral pathway on the other hand is not well defined; it follows the 
sympathetic and parasympathetic fibres, and transmits the information from 
organs located in the abdominal, thoracic and pelvic cavity (AIGÉ and CRUZ, 
2001). Parenchyma of the brain, liver and alveoli of the lungs are devoid of pain 
receptors. Nevertheless, the bronchi and parietal pleura are very sensitive to pain 
(STOELTING and HILLIER, 2006). Visceral nociceptor stimulation usually 
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produces pain that is poorly localized. However, within the spinal cord, the 
ascending pathway for visceral nociception coincides at least in part with that for 
somatic nociception (GRIMM and WAGNER, 2007). 
2.3. Sensitization (Wind up) 
Sensitization is the result of neural plasticity. Plasticity is defined as the capacity 
of the nervous system to modify its function in response to different 
environmental stimuli. These changes occur in the periphery (peripheral 
sensitization) and in the CNS (central sensitization) (CODERRE et al., 1993). 
In a clinical setting, even relatively innocuous wounds are associated with a 
degree of tissue inflammation able to initiate a cascade of sensitizing cellular 
events. Damaged cells and primary afferent fibres release a number of chemical 
mediators, which promote vasodilation with extravasation of plasma proteins and 
recruitment of inflammatory cells. The peripheral sensitization depends on 
vasoactive amines liberated from damaged tissue and inflammatory cells, and on 
the liberation of neuropeptides from nociceptive nerve endings (type C fibre). An 
inflammatory soup is created, composed of several vasoactive amines, ions and 
different subproducts of the arachidonic acid, that create a sensitizing environment 
(MUIR and WOOLF, 2001). This effect causes the originally high threshold 
nociceptors to respond to stimuli of low intensity (sleeping receptors). Sleeping or 
silent nociceptors are activated by inflammatory mediators and respond to 
mechanical and thermal stimulation only after they have been activated. The 
activation of these nociceptors contributes to the peripheral sensitization and the 
primary hyperalgesia (HARDY et al., 1950; RAJA et al., 1984). In addition to 
primary hyperalgesia associated with damaged tissue, pathological pain can also 
invoke an increased sensibility of neighbouring areas to noxious (secondary 
hyperalgesia) as well as to innocuous mechanical stimuli (allodynia) (HARDY et 
al., 1950; TOREBJÖRK et al., 1992; CODERRE et al., 1993). These clinical 
hypersensitivities (secondary hyperalgesia and allodynia) are a result of dynamic 
changes in dorsal horn neuron excitability, which modifies their receptive field 
properties. These stages are related to the duration of the synaptic action 
potentials generated by Aδ and C fibres. An action potential may last up to 20 
seconds, resulting in a summation of potentials and creating a progressively 
increasing and long-lasting depolarization in dorsal horn neurons (WOOLF, 
1983). This so-called “windup” of spinal neurons is
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receptors, which bind glutamate, and tachykinin receptors (WOOLF and 
THOMPSON, 1991; MELLO and DICKENSON, 2008). Other types of afferent 
neurons (large, myelinated Aβ fibres) respond to non-noxious stimuli (touch) but 
not to noxious stimuli directly. During central sensitization these fibres are 
recruited. Once the dorsal horn has been sensitized by nociceptive input, 
activation of Aβ fibre mechanoreceptors by previously innocuous tactile stimuli 
actually contributes to the pain response. In the dorsal horn, WDR neurons exhibit 
great activity and are largely involved in the encoding process of central 
sensitization whereas NS neurons do not participate intensively (MAIXNER et al., 
1986). The WDR neurons respond normally to innocuous stimuli but, once they 
are sensitized, they react to any stimulus and produce chronic central pain 
(DUBNER, 1990; ZHANG et al., 2005).  
In conclusion, the increase in spinal excitability is also accompanied by an 
increase in the receptive field, and in the duration and intensity of the stimulus 
response, leading to a hypersensible and hyperactive state at spinal levels. Both 
phenomena, the central and peripheral sensitization, are the fundamental basis for 
an analgesic approach that implies the preemptive administration of analgesic 
drugs before a noxious stimulus can trigger a sensitizing reaction (WOOLF and 
CHONG, 1993; LASCELLES et al., 1994; LASCELLES et al., 1997; HEYLLER, 
1999, SHAFFORD et al., 2001; TRANQUILLI et al. 2001; WATERMAN-
PEARSON, 2001; JIN and CHUNG, 2001; HELLEBRECKERS, 2002; 
GONZALEZ de MEJÍA, 2005).  
3. Pain as a pathology 
An important conceptual breakthrough in understanding pain physiology was the 
recognition that the pain occurring after most types of noxious stimulation is 
usually protective and quite distinct from the pain resulting from deliberate 
damage to tissues or nerves. This first type of pain is termed “physiologic pain”, 
and plays an integral adaptive role as part of the body’s normal defence 
mechanisms, warning of contact with potentially damaging environmental insults 
and initiating behavioural and reflex avoidance strategies (LAMONT et al., 2000). 
This type of pain requires noxious (high threshold) input, is discrete (well-
localized) and transient. Pathological pain, on the other hand, is defined as the 
type of pain that animals experience following severe trauma (e.g. surgery). It 
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subsequently requires non-noxious stimuli (low threshold), and it is diffuse and 
prolonged in duration. This type of pain does not serve a protective action 
(LEMKE, 2004). Pathologic pain is a physical and emotional experience that 
exceeds every beneficial effect (SHAFFORD et al., 2001; HELLEBRECKERS, 
2002). It provokes respiratory distress and increases the activity of the 
sympathetic nervous system which eventually causes metabolic and physiological 
dysfunctions like increasing serum concentrations of catecholamines, glucose and 
cortisol. Furthermore, the serum elevation of ACTH leads to the release of the 
antidiuretic hormone, aldosterone, renin and angiotensin II. All of these factors 
produce peripheral vasoconstriction, hence predispose to myocardial alterations 
and arrhythmias. Tachypnoea and dyspnoea decrease the partial pressure of 
oxygen and also promote the formation of atelectases and development of 
pneumonias (GAYNOR, 1999; GRECO and STABENFELDT, 2003; HELLYER, 
2007). Besides, the perception of pain causes an altered metabolic state and 
emotional suffering. It provokes anxiety and may provoke sleep deprivation 
leading to physic and psychic alterations which seriously complicate any healing 
process (wound dehiscence) (WOLFF and CHONG, 1993; LAUTENBACHER et 
al., 2006).  
4. Pain management 
4.1. Descending control of pain 
The CNS has its modulation system - a pain control mechanism in the spinal cord 
and in the brainstem (MILLAN, 2002). These descending pathways from 
brainstem and cortical structures have both facilitatory and inhibitory effects on 
nociceptive signalling in the dorsal horn and thalamus (HEINRICHER et al., 
2009). An increased inhibitory drive is presumably a homeostatic mechanism 
initiated in an attempt to counteract an enhanced facilitatory drive and increased 
spinal hyperexcitability (MELLO and DICKENSON, 2008). Thus, one can 
conceive that pathological processes may disrupt the equilibrium between 
excitatory and inhibitory influences, notably when inhibitory controls are lacking 
(LE BARS, 2002).  
The periaqueductal grey matter (PAG), rostral ventromedial medulla (RVM), the 
nucleus raphe magnus (NRM) and the locus coeruleus (LC) are all key brainstem 
sites for the modulation of nociceptive transmission in the spinal cord 
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(STAMFORD, 1995; HEINRICHER et al., 2009). The PAG projects to the RVM, 
which in turn sends its output mainly, although not exclusively to the superficial 
dorsal horn laminae, an important place for nociceptive processing and 
modulation. Recently, studies proved that descending control from the PAG 
differentially inhibits C- vs. A-fibre-evoked events in deep dorsal horn laminae 
but inhibits both C- and A-fibre-evoked events in lamina I (KOUTSILOU et al., 
2007).  
Descending modulation is exerted by three main neurochemical systems – the 
noradrenergic, serotonergic and opioidergic systems (TAVARES and LIMA, 
2007). Some neuromodulators that participate in this process are serotonin (5-
HT), endorphin and encephalin. More recently noradrenaline (NA) has been 
shown to have an equally important role in the control of pain. In this respect the 
alpha2-receptor subtype is responsible for the mediation of the antinociceptive 
effect (STAMFORD, 1995; MELLO and DICKENSON, 2008). The existence of 
several neurotransmitters and multiple receptors differentially modifies neuronal 
activity, corresponding to a bi-directional facilitatory and/or suppressive influence 
of certain mediators (MILLAN, 2002). The RVM, for example, is kwon for its 
biphasic effect (TODD, 2002). The NRM within the RVM forms a component of 
a descending inhibitory network that modulates nociceptive neurotransmission at 
the level of the spinal cord dorsal horn (MARINELLI et al., 2002). These can 
farther be influenced by the recruitment of RVM ON-cells and OFF-cells. When 
the ON-cells population is active, pain facilitation predominates, whilst an 
increase in OFF-cells population suppress pronociception (HEINRICHER et al., 
2009).  
Opioids are involved in both ascending and descending components of pain 
modulation. In the ascending part, all three receptors (µ, δ, κ) play an important 
role. The PAG is rich in opioid receptors and endogenous opioids and is a major 
target of analgesic action in the central nervous system. Moreover, moderate µ-
receptor binding is found in the dorsal raphe nucleus (DRN) and NRM with 
higher density in LC. It has been proposed that the analgesic effect of opioids on 
the PAG works by suppressing the inhibitory influence of the neurotransmitter γ-
aminobutyric acid (GABA) on neurons that form part of a descending 
antinociceptive pathway (STAMFORD, 1995; VAUGHAN et al., 1997). The 
PAG and NRM are under GABAergic inhibitory control and the microinjection of 
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GABAa receptor agonist into PAG causes hyperalgesia and also blocks the 
antinociceptive action of locally applied morphine (STAMFORD, 1995).  
4.2. Pain management 
Apart from the use of local anaesthetics total pain relief cannot be achieved by a 
single drug or method. Therefore combined anaesthetic regimens are more and 
more recommended. The rationale behind this strategy is to obtain profound 
analgesia due to additive or synergistic effects of different analgesics agents. This 
method is known as “balanced” or “multimodal analgesia”, and the goal is to 
achieve sufficient analgesia with concomitant reduction of side effects due to 
resulting lower drug doses (KEHLET and DAHL, 1993; STAMFORD, 1995; JIN 
and CHUNG, 2001). The reduced demand for analgesics with preservation of pain 
relief may be important in reducing side effects and thereby the need for 
postoperative surveillance. The concept of balanced analgesia may have an 
important impact on postoperative convalescence and morbidity (DAHL et al., 
1990). A study by LASCELLES et al. (1995) demonstrated a benefit by pre-
emptively using an analgesic drug at a clinically relevant dose rate. In order to 
prevent the onset of hypersensitivity probably the best approach is to administer 
analgesics both pre-, intra- and postoperatively (WOLF and CHONG, 1993). 
Analgesic drugs can act on different parts of the nociceptive pathway depending 
on their pharmacological properties. It is possible to combine different drugs and 
techniques to partially inhibit the release of inflammatory mediators and to 
decrease the conductance of the nociceptive information to superior levels 
(KEHLET and DAHL, 1993). At present, several analgesic techniques or a 
combination of these techniques are available to use: at the peripheral level local 
anaesthetics, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, 
opioids, and α2-agonists reduce or inhibit the transduction/ transmission of 
nociceptive information; at the spinal cord level the use of local anaesthetics, 
opioids, α2-agonists and NMDA-receptor antagonists may serve to inhibit central 
sensitization. At the cortical level the use of opioids, α2-agonists and hypnotic 
anaesthetics inhibits the perception of pain (fig. 4) (KEHLET and DAHL, 1993). 
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Figure 4: The site of action of the major classes of analgesics as they affect 
transduction, transmission, and modulation of nociceptive input and the 
perception of pain (TRANQUILLI et al., 2001). 
 
4.2.1. Opioids 
Opioids are the most effective analgesics, especially for moderate-to-severe 
postoperative pain. The discovery of the opioid receptor followed by the isolation 
and identification of the endogenous opioid peptides has had impact on the 
treatment of pain. The endogenous opioids, the enkephalins, dynorphins and 
endorphin family are all peptide in nature. Systemic opioids act both 
presynaptically to reduce neurotransmitter release and postsynaptically to 
hyperpolarize the membrane of dorsal horn neurons (DICKENSON, 1991; JIN 
and CHUNG, 2001). All of them have a similar mechanism of action, although 
the potency of the diverse receptor types is heterogeneous (µ-receptors, δ-
receptors and κ-receptors) (LORD et al., 1977). The nociceptive fibres also play 
an important role: in an experimental study electrical stimulation of the NRM led 
to inhibition of nociceptive information transmission mediated by the release of 
endogenous opioids. Opioids preferentially attenuated C-fibre activity (both pre- 
and postsynaptically) through µ- and δ- opioid receptors. Aδ fibres were 
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modulated only postsynaptically (JONES et al., 2003; LU et al., 2004).  
Some authors confirm the participation of spinal NO in the antinociceptive 
activity of systemically administered opioids (SONG et al., 1998).  A peripheral 
action is described, too, suggesting that opioids may specifically reverse the 
hyperalgesic effect of PGE2 and that NO formation through the L-arginine/ nitric 
oxide/ cGMP pathway may mediate this peripheral action (MAEGAWA and 
TONUSSI, 2003). After prolonged treatment a hyperalgesic effect of opioids has 
also been described. This opioid-induced increased pain sensitivity may be related 
to an inhibition of endogenous opioid release (HOOD et al., 2003; KOPPERT et 
al., 2003). However, several studies explain this delayed enhanced pain sensitivity 
through the capacity of opioids to increase the effect of glutamate at the NMDA-
receptor level. NMDA-antagonists like ketamine may have a beneficial effect on 
this pro-nociceptive effect and may potentially counteract the development of 
chronic pain processes (CÉLÈRIER et al. 2000; SIMONNET and RIVAT, 2003).   
Opioids posses several side effects, including nausea/vomiting, sedation, ileus, 
constipation, respiratory depression, and euphoria. All of them should be 
considered when using large doses of these drugs (DICKENSON, 1991; JIN and 
CHUNG, 2001). Opioids can be used for moderate or severe pain. Premedication 
with opioids may reduce the total dose of postoperative analgesia and can prevent 
central sensitization (WOLFF and CHONG, 1993; LASCELLES et al., 1995). 
Alternative analgesic drugs that potentiate the effect of opioids and contribute to a 
multimodal analgesia protocol include local anaesthetics, sedative drugs like α2-
agonists, NMDA receptor antagonists (ketamine) or anti-inflammatory drugs like 
NSAIDs or corticosteroids.   
4.2.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)  
The value of NSAIDs in minor, moderate or severe pain is well documented, and 
although this class of drugs represents an important component of the multimodal 
approach to postoperative pain treatment their analgesic efficacy is too small to be 
used as a sole analgesic in more severe pain states,. 
4.2.2.1. Mechanism of action 
4.2.2.1.1. Cyclooxygenase enzyme and prostaglandin synthesis 
Nonsteroidal anti-inflammatory drugs act by inhibiting the production of 
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prostaglandins (PGs) in the periphery and in the CNS (KEHLET and DAHL, 
1993). Prostaglandins are pharmacologically potent lipids widely distributed in 
mammalian tissues and body fluids. They belong to a group of compounds known 
as eicosanoids, a product of the polyunsaturated fatty acids (arachidonic acid) of 
plasmalemmal phospholipids. Prostaglandins act locally in the tissues where they 
are produced, and since they are rapidly inactivated, may be considered as “local 
hormones” (VANEGAS and SCHAIBLE, 2001). The role of PGE2 in 
inflammation has been elucidated and its pro-inflammatory potency is comparable 
with that of histamine, bradykinin, and serotonin. Indeed PGs have been reported 
to have leukotactic properties (PAULUS and WHITEHOUSE, 1973), and after 
injury, PGs - like other products of the arachidonic acid (AA) metabolism - 
promote pain and hyperalgesia associated with inflammation. The potentiation of 
bradykinin effects by PGs may stimulate synthesis and release of prostaglandins 
by activation of phospholipase A (VANEGAS and SCHAIBLE, 2001). 
Furthermore, PGs have an important effect on gastric and renal physiology, and 
possess a haemostatic function. They may inhibit gastric acid secretion, stimulate 
the production of mucus, and maintain renal blood flow (DAHL et al., 1991).  
Prostaglandins are synthesized by one of two enzymes: Cyclooxygenase 1 (COX-
1) or Cyclooxygenase 2 (COX-2). These two distinct isoforms of COX have been 
characterized. COX-1 is constitutively expressed and is involved in maintaining 
homeostatic functions, including the maintenance of gastric and renal integrity. In 
contrast the expression of COX-2 in neutrophils, macrophages, endothelial cells 
and fibroblasts is induced by growth factors, bacterial lipopolysaccharides, 
mitogens, and other proinflammatory stimuli (MARNETT, 2000). However, 
COX-2 is also constitutively expressed in the brain and spinal cord and it is 
present in neurons of all laminae, particularly laminae I-II but also in laminae III-
VI and X (VANEGAS and SCHAIBLE, 2001). More recently, a brain-specific 
splice variant of COX-1 has been identified in dogs, termed COX-3. This enzyme 
is a product of the COX-1 gene, but it is biologically different from COX-1 and 
seems to be less active in the synthesis of PGs (CHANDRASEKHARAN et al., 
2002; TERRENCE, 2006). 
 NSAIDs are usually defined as those agents that inhibit one or more reactions 
involved in the production of PG and thromboxanes (TX). The principal action of 
these drugs is the more or less selective blockade of COX-1 and COX-2 activity, 
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the first in a series of enzymes responsible for the conversion of AA to PG (fig. 4) 
(CARON, 2000). A secondary effect of COX-inhibitors has been proposed: COX-
inhibitors may make more arachidonic acid available for the synthesis of other 
compounds through the action of lipoxygenases. It has been shown that these 
lipoxygenase products lead to a decrease in GABAergic inhibition and thus an 
increase in postsynaptic neuron activity. In the PAG, this may lead to an enhanced 
descending nociceptive inhibition and thus antinociception at spinal levels 
(VANEGAS and SCHAIBLE, 2001).  
The efficacy of NSAIDs in absence of inflammation suggests that these agents 
might relief pain through a central mechanism. Data has confirmed their effect 
both on the spinal cord as well as on the brain (JURNA and BRUNE, 1990). In 
the brain COX-1 is present under inflammatory conditions and in the spinal cord 
nociceptive processes are mainly influenced by COX-2 (VANE et al., 1998; 
VANEGAS and SCHAIBLE, 2001). 
 
Figure 5: Representation of cyclooxygenase activity. COX-1 is constitutively 
expressed while COX-2 may be present by inflammatory processes (WOLFE et 
al., 1999).  
 
4.2.2.1.2. Nitric oxide synthase and COX inhibitors  
Recently, another mechanism of action of this class of drugs has been 
investigated. Regardless of their COX selectivity, some authors believe that the 
nitric oxide (NO)-cyclic guanylate monophosphate (cGMP) pathway plays an 
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important role for the induction of analgesia. It was shown that the antinociceptive 
action of several NSAIDs was reverted by the application of NO synthase 
inhibitors (L-NAME) and guanylate cyclase inhibitors (methylene blue) 
(DESOKY and FOUAD, 2005). Nitric oxide is a chemical messenger in a 
multitude of biologic systems, having homeostatic activity in the maintenance of 
cardiovascular tone, platelet regulation, and central nervous system signalling, as 
well as a role in gastrointestinal smooth muscle relaxation, and immune 
regulation.  NO may be one of the oldest biological molecules on earth and is 
synthesized by cell-specific isoforms of NO synthase (NOS) from the amino acid 
L-arginine. NOS has been broadly classified into a constitutive (cNOS) and an 
inducible (iNOS) subtype. The constitutive isoform is calcium- and calmodulin-
dependent, continuously expressed, and produces NO in picomolar 
concentrations. iNOS in contrast is calcium-independent and requires inducers 
such as specific cytokines or endotoxin for its expression (SCHROEDER and 
KUO, 1995; ELPHICK and SCHLEIFFER, 1997).  There are a lot of findings 
supporting an important role of the activation of the L-arginine-NO-cGMP 
pathway for antinociception. Not only in the periphery but also within the central 
nervous system it is possible to see a direct relation between acute 
hypernociception blockade and the stimulation of the L-arginine-NO-cGMP 
pathway (KNOWLES et al., 1989; DUARTE et al., 1992; SACHS et al., 2003).  
4.2.2.1.3. Endogenous opioid system  
Evidence clearly shows that not all NSAIDs act in the same way. COX inhibition 
may be one of the most investigated mechanisms of these anti-inflammatory 
drugs, but several studies suggest different antinociceptive pathways in the 
periphery that even involve the endogenous opioid system. DROGUL et al (2007) 
found that metamizole administered in the periphery causes antinociception 
probably through opioidergic mechanisms, since the application of naloxone 
reverted its effect. Naloxone pretreatment had no effect on the antinociceptive 
effects of other NSAIDs like diclofenac or ketorolac, suggesting differences in the 
mechanism of action among the NSAIDs. At the level of the brainstem the 
NSAIDs induce antinociception by activating the so called “descending pain-
control system”. This system is also activated by exogenous and endogenous 
opioids supporting the theory of a common pathway in the mechanism of action 
between both analgesics (VANEGAS and TORTORICI, 2002). Opioids like 
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fentanyl also reverse prostaglandin-induced hyperalgesia, probably by activating 
opioid receptors at the periphery or via the L-arginine/ nitric oxide/ cyclic-GMP 
pathway (MAEGAWA and TONUSSI, 2003). A similar mechanism of action can 
be seen with some NSAIDs (DESOKY and FOUAD, 2005). Although NSAIDs 
do not have a direct effect on the spinal cord, their analgesic action appears to be 
spinally mediated by activating inhibitory descending opioidergic mechanisms 
(LIZAGARRA and CHAMBERS, 2006). This means that a combination of 
opioids and NSAIDs leads to potentiation of the analgesic effects of both drugs 
(SHUG 2007). The potentiation has been experimentally and clinically approved 
in several studies (VAUGHAN et al., 1997; BERGMANN et al., 2007; 
RICHTER, 2007; LÓPEZ-MUÑOZ et al., 2008).  
4.2.2.2. COX selectivity 
Based on the nature and physiological actions of COX-1 and COX-2, the NSAIDs 
that preferentially block the production of COX-2-related PGs may be clinically 
superior to those with less COX-2 selectivity. Selective COX-2 inhibitors may be 
more desirable, because they inhibit the formation of PGs responsible for the 
clinical signs associated with inflammation, whereas their effect on COX-1 and its 
homeostatic properties is minor (CURRY and COOK, 2005). However, recent 
studies showed that the inhibition of COX-1 and not COX-2 mimics the action of 
the NSAIDs in the PAG (LEITH, 2007). Emerging information supports a role for 
COX-2 in the stomach having an impact on the gastrointestinal (GI) safety of 
COX-2-selective NSAIDs. COX-2 induction has been documented in 
Helicobacter pylori gastritis, inflammatory bowel disease, and bacterial infections 
of the gastric mucosa; thus, administration of COX-2 inhibitors in presence of GI 
inflammation may be harmful (TERRENCE, 2006). In a study by REUTER et al. 
(1996) the administration of selective COX-2 inhibitors to a rat model of colitis 
significantly inhibited the mucosal PG synthesis and notably increased colonic 
damage. In another study by LASCELLES et al. (2005) 69% of dogs treated with 
deracoxib, a selective COX-2 inhibitor, died or were euthanized because of GI 
tract perforation. However, all of them had received deracoxib at higher than 
recommended dosages or had received at least one other NSAID or 
glucocorticoid. Anyway, an important role of COX-2 in regulating ulcer healing 
has been demonstrated, and it is possibly mediated via PGD2 synthesis (PERINI 
and WALLACE, 2003; ZAMUNER et al., 2003) Taken together, COX-2 seems to 
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be required for GI defence, and ulcers may result from the inhibition of both 
enzymes (TERRENCE, 2006).   
4.2.2.3. NSAIDs drugs 
4.2.2.3.1. Carprofen 
Carprofen (Rimadyl®), a propionic acid derivate, was the first COX-2 selective 
drug approved for use in dogs. It is available in oral and injectable forms. The 
COX-2 selectivity of carprofen renders the oral form effective for long- and short-
term pain management. The primary difference in pharmacokinetics between the 
oral and injectable forms is their peak plasma concentration after drug 
administration: a single subcutaneous injection of carprofen results in a lower 
peak plasma concentration than the oral administration of the same amount. Like 
other NSAIDs, carprofen is highly protein bound in the blood, and it undergoes 
hepatic metabolism. Much of the drug is eliminated in the faeces (60% to 75%) 
and the remaining amounts are eliminated in the urine (CURRY and COOK, 
2005).  
Long-term oral administration of carprofen, compared with other NSAIDs, 
appears to have fewer GI side effects, possibly due to sparing the COX-1 
isoenzyme (LUNA et al., 2007). However, as mentioned, GI signs have been 
reported in some animals, thus monitoring for adverse effects must be performed 
when this drug is used. Carprofen is mainly indicated for the relief of pain and 
inflammation associated with osteoarthritis and for the control of postoperative 
pain associated with soft tissue and orthopaedic procedures in dogs (CURRY and 
COOK, 2005; TERRENCE 2006). The administration of carprofen for 28 days in 
dogs with osteoarthritis constituted a successful therapy without adverse effects, 
since the lameness score, measured on visual analogue scale, reduced significantly 
after treatment (2 mg kg-1 per day) (LIPSCOMB et al., 2002). Another study 
investigates the long-term use of carprofen (85 days) in dogs with chronic 
osteoarthritis and according to the veterinarians’ and owners’ assessments the 
results showed a 70% effectiveness of therapy (dogs free from lameness or signs 
less pronounced). The authors proposed that this percentage might be higher if the 
condition of the animals would have been recognized and treated earlier. Dogs 
suffering from chronic pain may require longer periods of treatment (MANSA et 
al., 2007). However, the administration of a different NSAID (firocoxib) clinically 
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showed a greater amelioration of the lameness associated with osteoarthritis in 
dogs compared to carprofen (POLLMEIER et al., 2006).  
After moderately painful surgery, the administration of full µ opioid agonists 
provides significantly better post-operative analgesia than carprofen. However, 
the widely recognized adverse effects of opioids may preclude the use of these 
agents (SLINGSBY, 2006). It has been shown that the sole use of NSAIDs 
(meloxicam or carprofen) might be effective in relieving pain after orthopaedic 
and soft tissue surgery (NOLAN AND REID, 1993; LASCELLES et al., 1998; 
GRISNEAUX et al., 1999; LAREDO et al., 2004; LEECE et al., 2005). Other 
authors recommend a balanced analgesic protocol and prefer a combination of 
local anaesthetics, systemic opioid agonists and carprofen, providing a safe and 
effective postoperative pain control after canine fracture repair (BERGMANN et 
al., 2007). Carprofen may prevent the inflammatory hyperalgesia and its 
combination with anti-hyperalgesic opioids like buprenorphine prevents the 
development of hypersensitive states after injury (TAYLOR et al, 2007). In the 
case of moderate pain (e.g. ovariohysterectomy) analgesia provided by the use of 
the NSAID meloxicam was shown to be clinically comparable to that of 
butorphanol (CAULCKET et al., 2003) 
4.2.2.3.2. Sodium Metamizole 
Sodium metamizole (Dipyrone, Vetalgin®) is a non-opioid analgesic derived 
from the pyrazolones with antipyretic and anti-inflammatory properties available 
as oral, rectal and injectable formulation. In aqueous solution metamizole is 
immediately hydrolysed to 4-methyl-amino-antipyrine (MAA), which is further 
metabolized to 4-amino-antipyrine (AA), 4-formyl-amino-antipyrine (FAA) and 
acetyl-amino-antipyrine (AAA). Of these four major metabolites, MAA has been 
demonstrated to be the pharmacologically active compound (VLAHOV et al., 
1990). After oral administration, metamizole is non-enzymatically hydrolyzed in 
the intestine and is rapidly and almost completely absorbed (ZYLBER-KATZ et 
al., 1992), its metabolites reaching maximal serum concentration in 1.5-2 hours in 
dogs (VOLZ and KELLNER, 1980). All metamizole metabolites are 
preferentially eliminated via urinary tract (VOLZ and KELLNER, 1980). The 
plasma protein binding of metamizole metabolites is relatively low; a higher 
binding affinity is observed for MAA and AA than for FAA and AAA (ZYLBER-
KATZ et al., 1985). Metamizole metabolites can cross the haematoencephalic 
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barrier (COHEN et al., 1998). 
Metamizole, like a lot of NSAIDs, may exert its effect on inflammatory pain 
through the inhibition of PG synthesis in both peripheral and central nervous 
system (CHANDRASEKHARAN et al., 2002). However, because metamizole is 
antipyretic and has little or no anti-oedematous effect, a central site of action may 
be highly implied. However, LORENZETTI and FERREIRA (1985) suggest only 
a peripheral action of metamizole and this may result from direct and dose-
dependent blockade of hyperalgesia rather than from prevention of the release of 
PGs in inflamed tissue. This can be explained with the findings of PIERRE et al. 
(2007), who suggest that the pharmacologically active metabolites of metamizole 
inhibit COX activity by sequestering radicals which initiate the catalytic activity 
of this enzyme. In the same study the data confirm an unlikely competition of 
MAA with arachidonic acid, as known to occur with traditional NSAIDs. 
REZENDE et al. (2008) also propose a peripheral both anti-hyperalgesic as well 
as a hypoalgesic action of metamizole. Although they insist in the involvement of 
COX activity, they could not prove the inhibition of PG biosynthesis as a direct 
cause of analgesic action of metamizole. In contrast with these studies, HINZ et 
al. 2007 found a pronounced inhibition of both COX-1 and COX-2 enzymes after 
oral administration of recommended doses of metamizole to humans. At 
therapeutic concentrations, a selective peripheral blockade of COX-2 has been 
described. This supports the view that a significant portion of metamizole´s 
analgesic action may be due to peripheral mechanisms (CAMPOS et al., 1999). 
On the other side, a central antinociceptive action of metamizole is attributed to 
the inhibition of central COX-3 leading to a reduced PGE2 concentration in the 
hypothalamic region. Despite being potent COX-3 inhibitors in cultured cells, 
many other NSAIDs are unlikely to reach comparable effective cerebral 
concentrations due to their highly polar structure (BOTTING and AYOUB, 2005). 
COX-3 inhibition and a resultant decrease of elevated cerebral PGE2 
concentrations in hyperthermic patients has also been proposed to be the major 
mechanism for acetaminophen’s antipyretic action (AYOUB et al., 2004), and the 
same may be true for metamizole.  
The analgesic properties of metamizole in the CNS may not only be due to its 
capacity to inhibit COX isoforms. Several studies support the involvement of 
descending pathways in the brainstem. CARLSON and JURNA (1987) provided 
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further evidence that metamizole produces a central antinociceptive and analgesic 
effect by stimulating spinal inhibition from the PAG. Moreover, they show that 
the supraspinal activation of descending pathways by metamizole can be 
potentiated by the spinal inhibitory action of morphine. Later, LORENZETTI and 
FERREIRA (1996) address the metamizole-mediated antinociception as a 
combined peripheral and spinal effect. Since the analgesic action of metamizole 
could be abolished with the application of L-NMMA (a nitric oxide synthase 
inhibitor) or methylene blue, it was proposed that its analgesic action results from 
the stimulation of the L-arginine/cGMP pathway. These findings also support a 
potentiating effect of metamizole in the antinociceptive action of opioids (SONG 
et al. 1998).  Other mechanisms which involve the opioid nociceptive control 
system have been investigated. In one study of TORTORICI and VANEGAS 
(1993), the microinjection of metamizole in the PAG of the rat resulted in 
antinociceptive responses in different tests, confirming a direct action of this 
NSAID on the PAG and providing evidence of involvement of medullary OFF- 
and ON-cells in such an antinociceptive effect. Newer findings of TORTORICI et 
al. (1996) support the theory of medullary OFF- and ON-cells. The administration 
of metamizole may stimulate the liberation of β-endorphins and its analgesic 
effect may be reverted by naloxone, suggesting that endogenous opioids are partly 
responsible for the antinociceptive action of metamizole. VAZQUEZ et al. (2005) 
also found an activation of the endogenous opioidergic circuit along the 
descending pain control system. This action may be mainly centrally mediated 
through the inhibition of nociception in spinal dorsal WDR neurons. 
On the other side, a peripheral action of metamizole associated with the activation 
of ATP-sensitive K+ channels has been described. This possibly involved the 
stimulation of the L-arginine/NO/cGMP pathway in sensory neurons, a 
mechanism also seen in opioid analgesia (ALVES and DUARTE, 2002) 
Interestingly, BEIRITH et al. (1998) refuse an association of ATP-sensitive K+ 
channel activation and the antinociceptive effect of metamizole, since the 
administration of glibenclamide (K+ channel blocker) did not significantly modify 
metamizole’s antinociceptive effect. In the same study L-arginine and naloxone 
failed to antagonize metamizole´s antinociceptive action, denying the activation of 
the L-arginine/NO/cGMP and the opioidergic system as one of the analgesic 
mechanisms of metamizole. The authors propose a modulatory effect on 
II. Literature    26 
glutamate-induced hyperalgesia as well as an interaction with glutamate binding 
sites.  
Despite the numerous behavioural and electrophysiological studies that have been 
performed, the mode and site of action of metamizole still remain controversial. 
 
Metamizole does not posses the same adverse effect as common pyrazolones at 
clinical doses. At doses of 300 mg/kg SID metamizole may provoke salivation, 
emesis, and weight loss due to reduced food intake. After a 4 weeks’ therapy of 
450 mg/kg SID serum values for BUN and alkaline phosphatise (ALP) were 
found to be elevated in the dog. However, no gastric ulceration was observed and 
a carcinogenic effect was only seen with the pyrazolone aminopyrine (KRAMER, 
1980). The administration of different doses of metamizole to the rat did not 
produce gastric mucosal injury compared with other NSAIDs like diclofenac 
(SÁNCHEZ et al., 2002a). In the same study the authors proved that gastric PGE2 
levels decreased in both groups similarly, suggesting that this diminuition of PGE2 
production may not be the only mechanism of damage. SÁNCHEZ et al. (2002b) 
also investigated the tolerability of metamizole and acetaminophen compared with 
diclofenac and found that unlike metamizole and acetaminophen, under diclofenac 
treatment blood loss, anaemia, and even impaired kidney function are observed. 
An endoscopic assessment in adult human volunteers has also been undertaken, 
and the administration for two weeks has shown effects on gastroduodenal 
mucosa comparable to those of paracetamol and placebo. Metamizole showed a 
great gastrointestinal tolerability and this fact is of particular value in the 
treatment of patients in whom NSAID are contraindicated (BIANCHI, 1996). The 
reason why metamizole does not produce gastric ulceration is still unknown. It is 
believed that its antispasmodic effect on vascular smooth muscle may increase the 
blood flow in the responsible tissues (ERGÜN et al., 2001). GÜLMEZ et al. 
(2008) found that metamizole increases the blood flow of arterial dorsal skin flaps 
in comparison with diclofenac in the rat. This relaxing effect of metamizole may 
be produced by an active nonenzymatic degradation product and it seems likely 
that 4-methylaminoantipyrine is the principle compound that leads to the observed 
relaxation. It is believed that the activation of the Na-K-ATPase pump may lead to 
this effect since the blockade with ouabain, a Na-K-ATPase pump inhibitor, 
inhibited the relaxation response of metamizole (ERGÜN et al., 1999). 
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There is little information of metamizole’s clinical efficacy in the dog. It is not 
used very frequently in small animal practice, whereas in equine medicine 
metamizole is often administered to treat colic pain and fever (ROBERTS and 
MORROW, 2001). In human medicine it is one of the most used analgesics to 
treat postoperative pain, acute pain, referred pain and migraine (EDWARD et al., 
2008). During mastectomy and retina surgery in humans metamizole and 
paracetamol have demonstrated similar analgesia (LANDWEHR et al., 2005; 
KAMPE et al., 2006). TORRES et al. (2001) found that metamizole and tramadol 
result in a similar pain relief after abdominal surgery in humans. Other authors 
failed to find good results with metamizole when compared with other NSAIDs 
like meloxicam or diclofenac, or opioids like tramadol (CANDER et al., 2005, 
YILMAZ et al., 2006). Metamizole appears to be a synergic analgesic in several 
studies: it improves the activity of other antinociceptive drugs and may even have 
a sparing effect. In an experimental rat model, LOPEZ-MUÑOZ et al. (2008) 
demonstrated an optimal morphine and metamizole combination. Both drugs 
produce a potentiation of their antinociceptive effects during intense pain. 
RICHTER (2007) found a marked intra-operative opioid-sparing effect during 
total hip replacement surgery in the dog.  
5. Pain evaluation 
5.1. Subjective methods 
The importance of providing good pain management in veterinary medicine is 
increasing substantially. However recent studies on the perioperative provision of 
analgesia in the small animal practice suggest that it is still suboptimal 
(LASCELLES et al., 1995). Pain recognition in the veterinary profession is 
problematic because animals are unable to verbally express their feelings and 
therefore the veterinarian must observe and interpret the animal’s behaviour and 
physiological changes as good as possible (BIANCHI et al., 2003).  HANSEN et 
al. (1997) found that physiological parameters do not change significantly after 
ovariohysterectomy in dogs and that compared to the measurement of heart rate 
and respiratory rate measurement of cortisol may be more accurate. In contrast, 
FOX et al. (1998) found that the intravenous application of butorphanol before 
ovariohysterectomy did not reduce the cortisol response after surgery. In fact, 
several studies have been performed on this topic and none of them could find a 
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direct relation between pain and increased values of cortisol in clinical settings, 
mainly because of the stress component. Plasma cortisol concentrations have 
failed to provide a useful measure under clinical conditions (MORTON and 
GRIFFITHS, 1985; FIRTH and HALDANE, 1999; REESE et al., 2001; 
SLINGSBY et al,. 2006; BERGMANN et al. 2007; EGGER et al,. 2007). On the 
other side pain indicators like respiratory rate, heart rate, blood pressure or 
increased body temperature are the most cited in the literature but there are few 
works that validate them (MORTON and GRIFFITHS, 1985). HOLTON et al. 
(1998b) found that respiratory rate and heart rate are not useful indicators of pain 
in hospitalised dogs. They used a subjective numerical rating scale (NRS) and 
correlated both subjective and objective data without satisfactory results. Because 
the individual conception and understanding of pain has a high variability 
between evaluators, observer variability must be taken into account when more 
than one observer is used. Besides the numerous scales used to asses pain lack 
validation (HOLTON et al., 1998a; HANSEN, 2003). The development of a scale 
to measure pain in animals is challenging, but the combination of behavioural and 
physiologic parameters seems to be useful and reliable to evaluate pain in dogs 
and their response to analgesics during the postoperative period. However, more 
studies will have to be done (FIRTH and HALDANE, 1999). Nowadays, most 
investigators use a combination of subjective observations (posture, activity, 
movements, and attitude) and objective measurements (respiratory rate, heart rate, 
pupil dilation, and body temperature) to evaluate pain in animals. All these 
observations are also useful for pain scoring on a visual analogue scale (VAS) 
(fig. 6). This scoring system consists of a 10 cm line, with 0 mm representing no 
pain and 100 mm the worst pain imaginable (BRODBELT et al., 1997; 
DENEUCHE et al., 2004; SLINGSBY et al., 2006). 
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Figure 6: Visual analogue scale (VAS) 
 
5.2. Objective methods 
A lot of attempts have been made to validate the utilization of an objective device 
to measure pain. The most frequently mentioned device is a pressure algometer, 
which basically consists of a pressure nociceptive threshold test. Studies in cats 
and dogs not undergoing surgery have shown good results and greater precision 
than thermal stimuli to asses pain threshold after administration of butorphanol, 
buprenorphine or carprofen (ROSA and MASSONE, 2005; DIXON et al., 2007; 
TAYLOR et al., 2007). A similar algometer has been used in cats given pethidine 
after castration and the results suggest that it could become useful to asses the 
effectiveness of analgesics agents (SLINGSBY et al., 2001). An alternative device 
commonly used in human medicine to test pain responses are the “Von Frey” 
monofilaments. “Von Frey” monofilaments are used to estimate tactile sensibility 
and with increasing bending force, the filaments will excite skin nociceptors and 
may determine tactile pain thresholds. In veterinary medicine they have been used 
to evaluate the analgesic effects of morphine in dogs (KUKANICH et al. 2005). 
Also exerting pricking pain this method is useful to determine primary and 
secondary hyperalgesia in humans (HARDY et al., 1950; CERVERO et al., 1993). 
In a study by KEIZER et al. (2007) “Von Frey” thresholds showed a good clinical 
correlation with the results of a NRS. Unfortunately in veterinary medicine dogs 
and cats often react before a painful stimulus has been evoked rendering this 
method unreliable for the estimation of pain in animals (BERGMANN et al., 
2007). 
5.2.1. Force plate analysis 
After limb surgery animals usually do not show a normal gait and frequently go 
lame. This may be due to a functional abnormality, but it normally occurs because 
of pain after surgery and the intent to avoid long lasting contact to the ground 
(indirect parameter of pain) (BUDSBERG et al., 1999). The human eye is not able 
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to capture the complexity of limb movements making an intra- and interindividual 
evaluation extremely difficult and, therefore, a visual grading of joint lameness 
might be limited (KOSFELD, 1996; BUDSBERG et al., 1996). Increasing interest 
in the biomechanics of motion has brought together various methods of analysis, 
including force plates, electrogoniometry, and cinematography. Being a useful 
non-invasive method to objectively determine the degree of postsurgical pain in 
dogs, the gait analysis has been used extensively to examine the gait and gait-
associated abnormalities, as well as the success of various modes of therapy 
(BUDSBERG, 1987; BENNETT et al,. 1996; EVANS et al., 2005). This system 
provides reliable information on the kinematic of the patient, as well as a precise 
analysis of the load distribution (kinetic) (MANLEY et al., 1990; ALLEN et al., 
1994; BERTRAM et al., 1997). Normally, 60% of a dog’s body weight is placed 
on the forelegs and on the hind legs only 40% (ROY, 1971). In a healthy dog the 
load should be regularly distributed so that each foreleg bears 30% and each hind 
leg 20%. This relation is described in stance but it also remains in movement 
(BUDSBERG et al., 1987) and it may be altered by patients with orthopaedic 
problems due to an animal’s tendency to avoid support on the injured leg (ROY, 
1971).  
The locomotion of the dog is described as a dynamic process, where the same 
pattern of movement occurs repeatedly in a cyclic sequence (DeCAMP et al., 
1993). As mentioned above, this dynamic process can be classified into kinetic or 
kinematic analysis. The measurement methods for the kinetic and the kinematic 
events are dynamometry (ground reaction force) and the kinemetry (motion 
analysis) respectively (OFF and MATIS, 1997). The dogs are analysed during 
walk or trot; the gait contains phases in which 2 or 3 legs are in contact with the 
ground, whereas in trot only two legs touch the ground at the same time 
(DeCAMP, 1997). 
5.2.1.1. Kinetic 
The kinetic is defined as the observation of the relation between a body’s 
movement and the corresponding forces (DeCAMP, 1997). The system measures 
the ground reaction force exerted during the stance of a gait. For better 
comparison between experimental protocols the ground reaction forces (GRF) are 
expressed in percent in relation to body weight (BW) (HUTTON et al., 1969). 
Later BUDSBERG et al. (1987) described the ground reaction forces (GRF) of 
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healthy dogs and expressed them in terms of vertical, craniocaudal and 
mediolateral vectors, Fz, Fy and Fx, respectively (fig. 7). Peak magnitude, 
duration and impulse in normal and pathological animals have been examined by 
measurement of vertical GRF (BUDSBERG, 1995).  
 
 
Figure 7: Direction of the ground reaction forces (GRF) in healthy dogs. Fz = 
vertical GRF, Fy = craniocaudal GRF and Fx = mediolateral GRF (extracted from 
BUDSBERG et al., 1987). 
 
The magnitude of the vertical GRF depends in part on the velocity of the 
locomotion (RIGGS et al. 1993). During walk this accounts for approximately 55-
70% of the animals BW and increases to 97-117% during trot (BUDSBERG et al., 
1987; HUTTON et al., 1969; JEVENS et al., 1993; DeCAMP 1997). The vertical 
GRF (Fz) is the greatest force compared to the craniocaudal and mediolateral 
forces and thus it is the most reliable and reproducible of all. The maximal 
vertical GRF (peak Fz) during stance is linearly related to morphometric data like 
length of humerus or femur, size of the paws or bodyweight. BUDSBERG et al. 
(1987) described values of peak forces up to 70% of the animals BW on the 
forelegs and up to 50% of their BW on the hind legs. The load distribution can 
also be calculated and is defined as a quotient.  
Another parameter that may be evaluated is the vertical impulse. The impulse is 
the force integral over a determined time, which means the total force that is 
applied during the stance phase (BUSBERG et al., 1987). The course of the 
vertical GRF can be divided in two intervals: the loading interval and the 
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unloading interval (fig. 8). It is interesting to know how rapidly a limb loads 
(severity of impact) and how long a limb accepts load. These data may provide 
additional specific information of limb function. Both parameters, severity of 
impact and acceptance of load, are measured in % BW per second or Newton (N) 
per second (BUDSBERG et al., 1995).   
 
 
Figure 8: Vertical force signals of the forelimb and the ipsilateral hind limb 
of a dog at a trotting gait, separated into the loading and the unloading 
intervals (BUDSBERG et al., 1993).  
 
The most common protocol consists of the dog being led on a leash by a handler 
on a platform containing force plates, but FACHON et al. (2006) proposed a 
modification of the traditional protocol by using a treadmill equipped with force 
sensors. This allows keeping the velocity constant and permits the simultaneous 
measurement of all limbs and assures a steady sequence throughout the entire 
recording process (OFF, 1992; KOSFELD, 1996; OFF and MATIS, 1997). As 
mentioned earlier this system provides reliable information about the gait and its 
features. A lot of studies have been made in order to validate different medical 
therapies. In one study of POY et al. (2000) healthy dogs and dogs with hip 
dysplasia were compared. The authors discovered a significant difference in the 
range of motion of the coxofemoral articulation between groups. The success of 
canine hip dysplasia treatment could also be evaluated through this method. After 
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triple pelvic osteotomy, the operated dogs transmitted significantly greater force 
than non-operated patients (McLAUGHLIN et al., 1991). MANLEY et al. (1990) 
also documented the success of cementless versus cemented total hip replacement 
in dogs. Within three months both groups returned to their preoperative ground 
reaction force levels on the implanted hind limb. For better comparison the 
authors propose the analysis of load distribution, because the cementless group 
showed a disparate load distribution between the operated and non-operated limb, 
whereas the cemented group demonstrated equal load distribution in both hind 
limbs.  Normally, the vertical forces are reduced greatly after total hip 
replacement in dogs compared with preoperative values but they return to normal 
values in magnitude and pattern after four months (DOGAN et al., 1989). Similar 
results were found by BUDSBERG et al. (1996) in a prospective study of dogs 
undergoing unilateral total hip replacement. Loading rates increased over the 
study period indicating willingness to load the operated hip. They also compared 
subjective lameness scores and objective GRF and found that the visual grading of 
coxofemoral joint lameness is limited. 
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III. OBJECTIVES 
The analgesic and anti-inflammatory action of NSAIDs in the periphery has been 
proven to be satisfactory compared to opioids in a lot of orthopaedic and soft 
tissue surgeries in animals (LAREDO et al., 2004; LAFUENTE et al., 2005; 
SLINGSBY et al., 2006). Even though NSAIDs do not always eliminate the need 
for supplementary analgesia during the postoperative period its use reduces the 
postoperative requirements for opioids (PIBAROT 1997; HELLYER et al. 1999).  
A combination of opioids and NSAIDs like metamizole or acetaminophen 
delivers satisfactory analgesia and, additionally, may reduce the adverse effects 
seen with opioids like morphine or tramadol (RAWAL et al., 2001; GEHLING 
AND TRYBA, 2008).  
Despite the fact that the author of this study believes that adequate pain relief is 
best achieved through the combination of several analgesics drugs, dogs included 
in this study received either metamizole or carprofen during the postoperative 
period. The aim of the application of only one analgesic drug was to evaluate the 
analgesic effect of metamizole as a sole agent compared to carprofen after 
orthopaedic surgery in dogs. 
 
In summary the objectives of this study are: 
• To evaluate the analgesic effect of recommended dosages of metamizole 
after canine total hip replacement.  
• To compare the analgesic effect of metamizole to that of recommended 
dosages of carprofen after canine total hip replacement. 
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IV. MATERIAL AND METHODS 
1. Patients 
Thirty-nine dogs weighing between 5.5 and 60.5 kg (no breed specificity) were 
included into this study. These animals were admitted to the small animal clinic 
for surgery and gynaecology of the Ludwig-Maximilians-University, Munich for 
an elective total hip replacement (THR). Dogs were only included into the study, 
if the clinical examination and results of the haematological and biochemical 
blood analysis revealed no abnormalities. Hence all animals were classified as low 
anaesthetic risk patients (ASA I/II). The dogs who presented any other pathology 
of the locomotion except for a coxarthrosis and patients who were previously 
treated with any other analgesics except nonsteroidal anti-inflammatory drugs 
(NSAIDs) were excluded. Owner approval was obtained before a dog entered the 
study. Dogs were housed and treated as clinical patients during the study period. 
2. Anaesthesia and analgesia 
Food was withheld for approximately 8 hours before induction of anaesthesia. 
Water was available ad libitum until shortly before premedication. All anaesthetic 
procedures were performed by the same anaesthetist (AS). After a clinical 
examination patients were premedicated with an intramuscular injection of 20 
µg·kg-1 acepromacin (Vetranquil® 1%, A. Albrecht GmbH & Co.KG, Zurich, 
Switzerland). Twenty minutes later an appropriately sized intravenous catheter 
was placed into one cephalic vein and induction of anaesthesia was then 
performed with 4 – 7 mg·kg-1 propofol IV (PropoFlo Vet® 1%, A. Albrecht 
GmbH & Co.KG, Aulendorf, Germany). After intubation of the trachea the 
animals were connected to a mechanical ventilator (Fabius Tiro, Dräger, Lübeck, 
Germany) and anaesthesia was maintained with isoflurane (Isoba®, Intervet, 
Unterschleißheim, Germany) (et1.5 vol.%) in an oxygen/air (50/50) mixture. 
During surgery a crystalloid infusion (Tutofusin, Baxter GmbH, 
Unterschleißheim, Germany) was administered at 10 ml·kg-1·h-1. Analgesia was 
achieved with a bolus of 2 µg·kg-1 of fentanyl IV (Fentanyl-Janssen®, Janssen, 
Neuss, Germany) given on the induction of anaesthesia followed by a continuous 
rate infusion (CRI) between 5 – 20 µg·kg-1·h-1 depending on the hemodynamic 
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parameters during the surgery. For perioperative infection prophylaxis, 20 mg·kg-1 
of lincomycin (Albiotic® AD.US.VET 300 mg, Pfizer GmbH, Karlsruhe, 
Germany) was intravenously administered after the induction of anaesthesia. 
Anaesthetic monitoring included electrocardiography, capnography, pulse 
oximetry, non invasive measurement of blood pressure, as well as measurement of 
body temperature.  
3. Surgery 
The operation was performed according to the modified method described by 
HOHN et al. (1986). After shaving and disinfection of the operating limb, dogs 
were placed in lateral recumbency. The approach to the hip joint was performed 
from craniolateral and through cranial mobilization of the m. tensor fasciae latae 
and partial tenotomy of the tendon of the m. glutaeus profundus.  After dissection 
of the joint capsule, the femoral head was dislocated and then removed by 
osteotomy. Subsequently, the articular surface was prepared to allow the 
implantation of the prosthesis. The acetabulum prosthesis was implanted with 10 
g methylmetacrilat, which normally hardens after 10 minutes. Following this the 
femur was prepared and 40 g cement was introduced from distal to proximal to 
implant the femur prosthesis. After hardening of the cement the artificial head was 
put on the femur prosthesis and then placed into the acetabulum. Finally the joint 
capsule was closed, the tendon of the m. gluteus profundus was reinserted and the 
wound was sutured. Upon completion of the surgery all patients were 
radiographically controlled and brought to the intensive station for recovery.  
4. Study design 
The study was conducted as a prospective, blinded and randomized clinical trial. 
After admission to the hospital, dogs were scheduled for surgery the following 
day. Patients were allocated to one of two groups, group C or group M. Dogs in 
group C (n=20) preoperatively received 4 mg·kg-1 of carprofen (Rimadyl®, Pfizer 
GmbH, Berlin, Germany) IV. For the following two days animals received the 
same dose of carprofen once daily. Animals in group M (n=19) received 50 
mg·kg-1 of sodium metamizole (Vetalgin®, Intervet GmbH, Unterschleißheim, 
Germany) IV at the end of surgery. Metamizole treatment was repeated every six 
hours on the day of the surgery and every eight hours on the following two days.  
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5. Pain assessment 
5.1. Pain scores 
All pain assessments were performed by one evaluator (AS). Three systems were 
used: a visual analogue scale (VAS) (fig. 6), a modified Melbourne pain scale 
(mMPS) (appendix 1) and force plate analysis. VAS is a subjective way to assess 
pain and consists of marking on a 100 mm line, labelled at one end “no pain” and 
with “very severe pain” at the opposite end. The observer has to place a mark on 
the line that corresponds to the pain intensity of the animal. The mMPS used for 
this study is based on eight variables considered to be relevant for pain assessment 
in previously published studies (PIBAROT et al., 1997; HOLTON et al., 1998; 
DENEUCHE et al., 2004; LAREDO et al., 2004; HOELZER et al., 2005): relative 
increase in heart rate, relative increase in respiratory rate, response to palpation of 
the injured/ operated area, vocalization, the animal’s activity and posture as well as 
the response to manipulation and to leading the animal out of the kennel. The 
mMPS consisted of firstly observing the animal’s behaviour while alone and 
undisturbed in its kennel. This allowed describing the patient’s activity and posture. 
Then the evaluator measured respiratory rate which was difficult on many 
occasions due to the dogs’ tendency to pant. In these cases the parameter 
“respiratory rate” was not considered for the evaluation. Next, the heart rate was 
counted by feeling digital palpation of the femoral pulse. Here it was very 
important to avoid unnecessary contact with the dogs in order to prevent patients to 
become excited. Once finished, the evaluator carefully touched around the wound 
and waited for a reaction. Then, the operated leg was passively mobilized waiting 
for a reaction, too. Finally, the dog was led on a leash out of the kennel to evaluate 
the degree of lameness. All of these observations were also performed for the 
visual analogue scale measurement.  
The pain score was obtained by summation of the scores given to the selected 
variables and ranged from a minimum value of 0 to a maximum of 24. Both scales 
were used for pain assessment 3, 6, 9, 12, 20, 24, 28, 32, 36, 44, 48 and 56 hours 
after the end of surgery (T0, T3, T6, T9, T17, T21, T25, T29, T33, T41, T45 and T53 
respectively). The first evaluation was made three hours after the end of surgery. 
This was achieved approximately 2.5 hours after extubation in all patients. Once 
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the patients were extubated, a brief pain evaluation was made to ensure the 
patients’ wellbeing and during the next hours they were under observation of a 
veterinarian and/or a technician. If a dog showed signs of pain before T0, the 
evaluator (AS) was called to score the animal’s pain by means of VAS and 
mMPS. If the VAS or mMPS scores reached values of or above 50 or 12, 
respectively, rescue analgesia was immediately provided. It was administered 
intravenously and consisted of 10 µg·kg-1 of buprenorphine (Buprenovet®, Bayer 
AG, Leverkusen, Germany). Dogs that received rescue analgesia were excluded 
from their group and the statistical analysis but pain evaluation was continued. 
5.2. Force plate analysis 
In order to evaluate the degree of lameness, all patients were subjected to a force 
plate analysis, once preoperatively (preOP) and then on the first (OP1) and second 
postoperative day (OP2). The examinations of all dogs were done in the same 
room and by the same person (AS). In the centre of this room a podium (approx. 
5.7m long, 1.2m wide and 28cm high), which holds the treadmill, has been built. 
The treadmill is made up of two parallel belts, which are visible over a length of 
140cm and a width of 80cm. Four kistler force plates (70cm length and 40 cm 
width) lie under these two belts. The force plates are connected to a computer via 
an amplifier and a signal transducer. Fine tuning of the treadmill’s speed is 
possible to 0.02 m·s-1. The speed in this study was set according to the patient’s 
acceptance, but variability between dogs was avoided.  
The measurement of ground reaction forces took place at 1000 Hz. After 
recording, all data were then exported to an ASCII-file. Steps with correct first 
ground contact, and steady and regular pace were selected by proprietary 
Software. Then the kinetic results were distributed and saved in numeral and 
graphical form.  
For this study, only peak vertical force (PVF) and vertical impulse (VI) were 
considered.  To reduce variability only the data of the hind legs were analysed. All 
dogs were subjected to preoperative analysis (preOP), and then on the first and 
second day after surgery, respectively. The values of the contralateral (not 
operated) hind limb (nop) were considered as 100% each day and the percentage 
of the operated limb (op) respective to nop were calculated for dogs in group M 
and C. These results were compared and analysed statistically for preOP, OP1 and 
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OP2. Differences between preOP, 1OP and 2OP for each group were also 
compared and analysed statistically. 
6. Statistical analysis 
Weight, age, surgery time, anaesthesia time, amount of intraoperatively 
administered fentanyl as well as treadmill velocity were statistically analysed with 
the Man Whitney Test, SPSS 17.0. Results of pain scores (VAS, mMPS) were 
analysed with the same test. Data obtained on the treadmill were analyzed with a 
T-test. The level of significance was set at p < 0.05.  
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V. RESULTS 
Thirty-nine dogs (no breed specificity) with a mean body weight of 32.7 + 9.8 kg 
BW (5.5 kg to 60.5 kgBW) and with a mean age of 4.2 + 3 years (8 months to 12.3 
years) were enrolled in this study.  Twenty dogs received carprofen (4 mg·kg-1) 
once daily and nineteen dogs received sodium metamizole (50 mg·kg-1) three times 
a day. Ten dogs (25.6%) were intact males, nine (23.1%) were intact females, nine 
(23.1%) were castrated males and eleven (28.2%) were spayed females (table 1).  
 
Table 1: Gender distribution in the groups 
Sex Metamizole Carprofen Total 
Male 7 4 11 
Female 4 5 9 
Neutered male 5 3 8 
Spayed female 3 8 11 
Total 19 20 39 
 
Twenty dogs (51%) were operated on the left leg, ten in group M and ten in group 
C. Nineteen dogs (49%) were operated on the right leg, 10 in group C and nine in 
group M (table 2). No statistical differences were seen in age, body weight, 
duration of anaesthesia, duration of surgery and intraoperative fentanyl 
requirements between groups (table 3). 
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Table 2: Data of the patients 
N° Race Group Weight (kg) 
Age 
(months) Indication of Surgery Side 
1 Labrador M 34 55 severe bilateral 
coxarthrosis Right 
2 Labrador 
mix M 37.5 100 
severe bilateral 
coxarthrosis Right 
3 German 
shepherd M 36 16 
 mild bilateral 
coxarthrosis Right 
4 Golden 
retriever M 26 10 
hip dislocation and mild 
bilateral coxarthrosis Left 
5 Mongrel dog M 28 8 
hip dislocation and mild 
bilateral coxarthrosis Left 
6 Schnauzer 
mix C 13.5 8 
hip dislocation and 
moderate bilateral 
coxarthrosis 
Right 
7 Hunting dog C 29 54 
severe coxarthrosis on 
left side Left 
8 
Bernese 
mountain 
dog 
M 39.5 22 severe bilateral 
coxarthrosis Right 
9 
Bernese 
mountain 
dog 
M 36.7 12 hip dislocation and mild bilateral coxarthrosis Left 
10 Pekinese C 5.6 67 
femoral head defect left 
side (Legg Calve Perthes 
disease) 
Left 
11 German 
shepherd C 33.3 91 
severe bilateral 
coxarthrosis Right 
12 
German 
shepherd 
mix 
C 24.6 19 severe coxarthrosis on 
right side Right 
13 Labrador M 34 50 severe coxarthrosis on left side Left 
14 Schanuzer 
mix M 40 79 
severe coxarthrosis on 
right side, mild 
coxarthrosis on left side 
Right 
15 Mongrel dog M 50.7 148 
severe bilateral 
coxarthrosis Right 
16 Labrador C 34.5 102 severe bilateral 
coxarthrosis Left 
17 Labrador C 23.6 90 severe bilateral 
coxarthrosis Left 
18 Golden 
retriever M 30.5 138 
severe bilateral 
coxarthrosis Right 
19 
Bernese 
mountain 
dog 
C 60.5 81 severe bilateral 
coxarthrosis Right 
20 
German 
shepherd 
Mix 
C 37.5 Unknown severe bilateral 
coxarthrosis Left 
21 Dobermann C 26.6 120 severe bilateral 
coxarthrosis Left 
22 Labrador C 26 50 severe bilateral 
coxarthrosis Left 
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23 German 
shepherd C 37 36 
severe bilateral 
coxarthrosis Right 
24 Mongrel dog M 20 115 
severe bilateral 
coxarthrosis Left 
25 German 
shepherd C 37.5 58 
severe coxarthrosis on 
right side, hip prosthesis 
leftside 
Right 
26 German 
shepherd C 41.2 98 
severe bilateral 
coxarthrosis Left 
27 Golden 
retriever C 47.7 96 
severe bilateral 
coxarthrosis Right 
28 Labrador 
mix C 30.6 47 
severe bilateral 
coxarthrosis Right 
29 Labrador 
mix C 34 108 
severe coxarthrosis on 
left side, hip prosthesis 
on right side 
Left 
30 Mongrel dog M 36 79 
severe bilateral 
coxarthrosis Right 
31 
Old 
german 
shepherd 
M 33.4 97 
severe coxarthrosis on  
left side, mild 
coxarthrosis on right side 
Left 
32 Rhodesian 
ridgeback M 36.5 8 
hip subluxation and 
atrophy of the neck on 
left side 
Left 
33 Golden 
retriever M 33 8 
hip dislocation both 
sides, mild bilateral 
coxarthrosis 
Left 
34 Irish setter M 45.5 84 severe bilateral 
coxarthrosis Left 
35 Airdale terrier C 25 96 
severe coxarthrosis on 
left side, mild 
coxarthrosis on right side 
Left 
36 
German 
shepherd 
mix 
M 28 36 
hip dislocation both 
sides, moderate bilateral 
coxarthrosis 
Left 
37 Mongrel dog C 32.7 15 
moderate coxarthrosis on 
right side, hip prosthesis 
on left side 
Right 
38 Mongrel dog M 20.5 11 
Bilateral hip dislocation, 
mild bilateral 
coxarthrosis 
Left 
39 Comondor C 43.8 Unknown 
moderate coxarthrosis on 
left side, mild 
coxarthrosis on right side 
Left 
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Table 3: Average body weight, age, anaesthesia time, surgery time and 
amount of intraoperative fentanyl in both groups 
Group Weight (kg) + SD 
Age (years) + 
SD 
Anaesthesia 
time (min) + 
SD 
Surgery time 
(min) + SD 
Intraoperative 
fentanyl 
(µg/kg/h) + SD 
M 33.59 + 7.34 4.74 + 3.93 276.67 + 25.95 97.68 + 9.79 9.77 + 2.93 
C 32.21 + 11.56 5.62 + 2.77 286.47 + 22.83 97.45 + 12.25 11.67 + 3.92 
 
None of the patients presented a surgical complication. All animals woke up from 
the anaesthesia without major adverse reactions. During the stay in the hospital six 
patients (15.4%) presented diarrhoea. Five of them belonged to group M and only 
one to group C. Three patients belonging to the group M (7.7%) vomited during the 
course of the study. One of them developed excessive vomiting and the metamizole 
therapy was discontinued. This patient was immediately excluded from the study 
and the following evaluations.  
1. Pain scores 
All dogs could be subjectively evaluated with both pain scoring systems (mMPS 
and VAS) except for one patient that became aggressive despite the administration 
of rescue analgesia. Due to his temper evaluations could not be performed after T25.  
1.1. Rescue analgesia 
Out of the 39 patients evaluated, three needed rescue analgesia (10 µg·kg-1 
buprenorphine IV) (table 4 and 5) and were subsequently excluded from the 
statistical analysis and did not participate in the gait analysis. All of these patients 
were in group C. One of them scored 61 points for VAS and 19 points for mMPS 
immediately after extubation. The dog quickly received the rescue analgesia and by 
the next evaluation (T0) the scores had decreased to 41 for VAS and to 10 for 
mMPS (data not shown). The other two dogs woke up without problems, but by the 
first evaluation (T0) they scored 50 and 74 points for VAS and 14 points for 
mMPS. The patient who showed 74 points for the VAS did not respond well to the 
initial therapy with 10 µg·kg-1 buprenorphine and hence the same dose of 
buprenorphine was repeated for a second time. The following assessment (T3) still 
revealed a VAS score greater than 50 and it was decided to administer metamizole 
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(50 mg·kg-1) IV. Because the study was blinded, the evaluator (AS) did not know 
that this time metamizole and not buprenorphine was administered. The scores at 
the following evaluation (T6) had decreased to10 points for mMPS, but remained at 
50 points for VAS. From T25 on it was impossible to conduct any further pain 
evaluation because the dog was too aggressive. The patient continued on 
buprenorphine (10 µg·kg-1 TID) and metamizole (50 mg·kg-1 TID). The last dog 
that received rescue analgesia responded very well to the therapy: at T3 VAS and 
mMPS scores went down from 50 to 26 points and from 14 to 4 points, 
respectively (figure 9 and 10).  
 
Table 4: mMPS scores rescue analgesia. mMPS = modified Melbourne Pain 
Scale; ID = identification number; * = pain evaluation immediately after 
extubation; ** = impossible to evaluate because of aggression. 
ID T0 T3 T6 T9 T17 T21 T25 T29 T33 T41 T45 T53 
100637 14 12 10 10 9 8 **      
100699 14 4 8 7 6 4 2 3 3 3 2 1 
101989 19* 9 11 6 8 4 4 4 4 3 4 2 
 
Table 5: VAS scores rescue analgesia. VAS = visual analogue scale; ID = 
identification number; * = pain evaluation immediately after extubation; ** = 
impossible to evaluate because of aggression 
ID T0 T3 T6 T9 T17 T21 T25 T29 T33 T41 T45 T53 
100637 74 58 52 50 50 45 **      
100699 50 26 43 39 34 32 15 27 25 25 22 14 
101989 61* 41 50 30 31 29 24 25 25 20 21 20 
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Figure 9: mMPS score before and after rescue analgesia. 
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Figure 10: VAS score before and after rescue analgesia. 
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1.2. Modified Melbourne pain score (mMPS) 
The results of the mMPS assessments are shown in table 6 and 7. 
 
Table 6: mMPS scores and mean values over the time for dogs in group M. 
SD = standard deviation; ** = patient excluded because of excessive 
vomiting; * = patient went home 
ID T0 T3 T6 T9 T17 T21 T25 T29 T33 T41 T45 T53 
100400 4 4 4 3 4 4 2 1 0 1 0 1 
96614 4 5 7 4 2 2 2 2 2 2 3 1 
98905 5 5 6 6 3 5 7 4 4 4 3 3 
99749 9 4 3 3 4 3 3 1 3 5 2 0 
101107 6 5 4 6 6 5 3 5 3 4 2 2 
95791 6 9 8 4 3 3 3 4 3 1 3 3 
102408 8 6 5 4 4 4 2 2 5 1 2 1 
101516 8 9 5 4 7 3 3 4 4 1 3 2 
101313 5 5 5 3 3 4 2 1 1 0 1 1 
101656 4 3 6 2 5 4 3 2 1 1 0 * 
101886 7 6 5 4 3 3 3 2 1 2 2 0 
101872 7 9 9 9 9 7 4 4 2 4 1 1 
99283 8 4 6 8 6 3 1 1 0 2 1 1 
103480 11 3 5 4 2 3 0 0 1 2 1 0 
103521 9 9 9 6 9 7 7 5 4 3 3 2 
103369 5 4 5 6 3 2 1 0 0 1 0 0 
96051 5 5 3 2 2 4 **           
100842 4 4 4 4 3 4 1 0 0 2 2 0 
102611 9 8 7 5 5 6 5 5 5 3 3 * 
Mean + 
SD 
6.63 
+ 
2.09 
5.69 
+ 
2.12 
5.63 
+ 
1.78 
4.88 
+ 
1.78 
4.44 
+ 
2.27 
3.88 
+ 
1.5 
2.75 
+ 
1.94 
2.25 
+ 
1.8 
2.06 
+ 
1.69 
2.19 
+ 
1.42 
1.81 
+ 
1.04 
1.13 
+ 
1.02 
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Table 7: mMPS scores over time for dogs in group C. SD = standard deviation;   
* = patient went home. 
ID T0 T3 T6 T9 T17 T21 T25 T29 T33 T41 T45 T53 
100880 9 7 8 8 7 7 6 6 6 6 7 8 
100698 9 8 9 6 11 6 10 5 4 5 11 9 
101487 5 6 6 8 7 6 5 5 2 3 5 3 
101488 6 6 6 6 4 6 6 5 3 3 6 5 
101841 10 9 6 10 6 7 3 3 4 4 5 3 
95904 8 10 10 10 8 6 6 4 5 3 4 2 
102431 7 7 6 5 3 7 3 2 1 4 0 0 
101975 4 7 10 9 8 6 5 3 5 2 2 2 
102086 8 8 7 5 5 2 2 1 4 0 0 0 
102347 9 5 8 8 11 3 8 5 3 5 3 2 
96359 5 4 0 2 0 0 3 0 0 0 3 0 
102404 7 6 4 5 5 4 2 2 2 1 1 2 
102628 11 6 4 5 5 5 5 2 2 5 3 1 
94614 5 7 6 9 8 6 4 3 4 4 3 1 
91538 6 5 7 7 7 7 4 5 6 5 3 3 
101107 7 6 3 3 7 8 6 7 8 4 6 6 
103969 9 8 6 4 3 6 4 4 4 4 2 * 
Mean + 
SD 
7.25 
+ 
2.02 
6.69 
+ 
1.54 
6.25 
+ 
2.62 
6.63 
+ 
2.39 
6.38 
+ 
2.78 
5.38 
+ 
2.13 
4.88 
+ 
2.16 
3.63 
+ 
1.93 
3.69 
+ 
2.06 
3.38 
+ 
1.82 
3.88 
+ 
2.8 
2.94 
+ 
2.74 
 
Except for the three dogs that received rescue analgesia mMPS scores revealed 
good pain relief for both groups during the entire evaluation period (pain score < 
12). At T0, scores in both groups were over 6 points and no statistical differences 
were found (p = 0.21). At the next evaluation (T3), scores of dogs in group M had 
decreased to 5.69 + 2.12. Scores of dogs in group C remained over 6 points (6.69 
+ 1.54) and did not decrease until T21 (5.38 + 2.13). A significant difference 
between the groups was found at T3 (p = 0.04) and between T9 and the end of the 
study (p < 0.05). Dogs in the group M showed lower mMPS scores during the 
whole study (table 8, figure 11). 
 
 
 
 
 
 
 
V. Results    48 
Table 8: mMPS mean values for dogs in group M and C. SD = standard 
deviation; p = significance level < 0.05. 
 
Evaluation time Group M Group C Mann Whitney Test 
  
Mean + SD Mean + SD P 
T0 6.63 + 2.09 7.25 + 2.02 0.21 
T3 5.69 + 2.12 6.69 + 1.54 0.04 
T6 5.63 + 1.78 6.25 + 2.62 0.19 
T9 4.88 + 1.78 6.63 + 2.39 0.02 
T17 4.44 + 2.28 6.38 + 2.78 0.02 
T21 3.88 + 1.50 5.38 + 2.13 0.01 
T25 2.75 + 1.95 4.88 + 2.16 0.01 
T29 2.25 + 1.80 3.63 + 1.93 0.05 
T33 2.06 + 1.69 3.69 + 2.06 0.03 
T41 2.19 + 1.42 3.38 + 1.82 0.03 
T45 1.81 + 1.05 3.88 + 2.80 0.01 
T53 1.13 + 1.03 2.94 + 2.74 0.04 
 
,00
2,00
4,00
6,00
8,00
10,00
12,00
T0 T3 T6 T9 T17 T21 T25 T29 T33 T41 T45 T53
Time (hours)
m
M
PS
 
sc
o
re
Metamizol +/- SD
Carprofen +/- SD
 
Figure 11: mMPS score over time for dogs in the group M and C.  
* = statistically significant differences (p < 0.05). 
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1.3. Visual analogue scale (VAS) 
The results of the VAS scores are shown in table 9 and 10. 
 
Table 9: VAS scores over time for dogs in group M. SD = standard deviation;  
** = patient excluded because of excessive vomiting; * = patient went home 
ID T0 T3 T6 T9 T17 T21 T25 T29 T33 T41 T45 T53 
100400 33 31 26 28 22 23 25 14 17 11 9 5 
96614 42 40 37 40 29 24 19 12 18 13 13 6 
98905 31 33 35 43 38 38 37 27 29 27 25 21 
99749 39 40 27 30 29 25 26 20 19 23 19 17 
101107 39 43 30 34 35 30 30 26 24 26 17 17 
95791 37 41 41 37 35 31 33 34 30 24 28 26 
102408 46 41 37 33 29 27 29 23 25 25 23 20 
101516 43 47 32 30 27 27 28 27 27 22 20 22 
101313 26 25 29 21 23 20 13 8 9 5 6 5 
101656 20 27 27 25 19 28 22 20 15 12 11 * 
101886 32 35 29 31 31 25 24 24 22 22 20 11 
101872 41 39 42 39 43 29 27 23 23 27 15 15 
99283 33 29 32 31 31 15 14 11 0 8 0 0 
103480 39 31 22 22 17 18 10 7 5 8 7 0 
103521 32 32 35 24 32 22 24 20 20 21 14 12 
103369 21 16 17 17 13 11 6 0 0 0 0 0 
96051 25 21 19 19 15 20 **      
100842 27 26 26 20 20 25 10 6 5 4 8 0 
102611 44 42 39 34 30 35 27 25 20 23 20 * 
Mean + 
SD 
34.21 
+ 
7.81 
33.63 
+ 
8.31 
30.63 
+ 
7.07 
29.37 
+ 
7.58 
27.26 
+ 
8.08 
24.89 
+ 
6.55 
22.44 
+ 
8.65 
18.17 
+ 
9.13 
17.11 
+ 
9.53 
16.72 
+ 
8.98 
14.17 
+ 
8.1 
11.25
+  
8.93 
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Table 10: VAS score over time for dogs in group C. SD = standard deviation; 
* = Patient went home 
ID T0 T3 T6 T9 T17 T21 T25 T29 T33 T41 T45 T53 
100880 46 44 44 49 37 34 32 31 31 31 32 39 
100698 45 46 44 39 43 39 43 45 40 39 33 44 
101487 40 37 41 44 35 37 33 32 29 29 44 31 
101488 42 43 42 46 42 46 40 30 30 29 36 29 
101841 43 39 38 35 35 39 36 30 26 28 27 26 
95904 40 43 43 43 35 40 30 30 32 29 29 19 
102431 31 32 25 24 21 24 16 14 16 10 11 5 
101975 11 23 46 31 30 27 25 24 24 16 12 8 
102086 31 32 31 28 24 19 16 15 21 7 0 0 
102347 36 27 30 32 29 24 26 28 29 28 25 20 
96359 28 22 23 23 11 6 14 9 0 0 12 0 
102404 32 29 23 26 19 17 14 17 15 12 13 12 
102628 46 30 27 25 33 29 28 19 19 24 19 7 
94614 31 43 39 39 43 32 25 17 21 23 20 13 
91538 42 40 42 40 42 34 32 28 30 31 24 19 
101107 39 36 30 30 32 36 34 31 29 26 28 28 
103969 39 32 33 25 27 29 20 23 27 23 17 * 
Mean + 
SD 
36.59 
+ 
8.75 
35.18 
+ 
7.52 
35.35 
+ 
8.01 
34.06 
+ 
8.47 
31.65 
+  
9.1 
30.17 
+ 
9.96 
27.29 
+ 
8.97 
24.88 
+ 
8.87 
24.65 
+ 
8.96 
22.65 
+ 
10.23 
22.47 
+ 
11.02 
18.75 
+ 
13.33 
 
Except for the three dogs that received rescue analgesia VAS scores revealed good 
pain relief for both groups during the entire evaluation period (VAS score < 50). 
From T0 to T17 both groups scored quiet similar and no statistical differences were 
found until T21 (p = 0.05). Except for T25 (p = 0.11) and T53 (p = 0.11) the 
following evaluations showed significant differences, too (p < 0.05). Group M 
showed lower VAS scores during the whole study period (table 11, figure 12).  
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Table 11: VAS mean values for dogs in group M and C. SD = standard 
deviation; p = significance level < 0.05. 
 
Evaluation period Group M Group C Man Whitney Test 
 Mean + SD Mean + SD P 
T0 35.06 + 6.86 36.44 + 9.02 0.30 
T3 34.31 + 8.01 35.38 + 7.72 0.46 
T6 31.06 + 6.73 35.5 + 8.25 0.07 
T9 30 + 7.67 34.63 + 8.41 0.12 
T17 28.38 + 7.87 31.94 + 9.32 0.11 
T21 24.38 + 6.49 30.19 + 10.29 0.05 
T25 22.19 + 9.13 27.75 + 9.06 0.11 
T29 17.63 + 9.54 25 + 9.15 0.04 
T33 17.06 + 10.1 24.5 + 9.24 0.02 
T41 16.63 + 9.34 22.63 + 10.56 0.03 
T45 14 + 8.45 22.81 + 11.29 0.02 
T53 11.06 + 8.93 18.75 + 13.33 0.09 
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Figure 12: VAS score over time for dogs in the group M and C. 
* = statistically significant differences (p < 0.05). 
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2. Ground reaction forces (GRF) 
Force plate analysis was performed in thirty-four patients (94.4%). Only one dog in 
group C did not tolerate the examination for unknown reasons and one dog in 
group M was a measurement error. The examination was possible in eighteen dogs 
of group M (94.7%) and sixteen dogs of group C (94.1 %). During the preoperative 
gait analysis dogs in group C and M walked at a speed of 0.62 + 0.06 m/s and 0.67 
+ 0.1 m/s, respectively. As expected, the speed of the treadmill had to be slowed 
down for the postoperative examinations. On the first and second postoperative 
days the speed for animals in group C was decreased to 0.05 + 0.03 m/s and 0.03 + 
0.03 m/s, respectively. For dogs in group M it was decreased to 0.04 + 0.05 m/s 
and 0.03 + 0.05 m/s on the first and second postoperative days, respectively. This 
reduction in speed was significant in both groups, but between groups no statistical 
speed differences were found. 
Except for three dogs in group M all patients tolerated the examinations well. Of 
these three dogs, one refused to walk on the treadmill on the first postoperative day 
and two refused to walk on the treadmill on the second postoperative day.  
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2.1. Peak vertical force 
The peak vertical force (PVF) of the hind limbs were measured and expressed in 
percentage of body weight (%BW). Then a relation between the values obtained 
for the operated hind limb and the contralateral non operated hind limb was 
calculated and expressed as a percentage (op/nop%). Data are shown in tables 12 
and 13. 
 
Table 12: Peak vertical force (%BW) of dogs in the group M. preOP = 
preoperative day; OP1 = first postoperative day; OP2 = second postoperative 
day. Op = operated hind limb; nop = non operated hind limb; * = patient 
refuse to walk. 
  preOP   OP1   OP2  
ID Op nop op/nop% op nop op/nop% Op nop Op/nop% 
95791 35.8 35.9 99.72 32.6 36.5 89.32 31.2 34.2 91.23 
98095 38.8 35.3 109.92 34.3 39.4 87.06 36.4 41.7 87.29 
96051 39.0 38.2 102.09 36.1 42.3 85.34 * *  
99283 34.0 36.3 93.66 36.0 40.6 88.67 32.4 36.0 90.00 
99749 36.6 41.0 89.27 37.0 44.4 83.33 36.0 40.7 88.45 
100400 34.9 35.6 98.03 * *  34.8 36.9 94.31 
100842 35.2 34.1 103.23 36.1 40.8 88.48 36.6 38.7 94.57 
101107 30.5 33.9 89.97 28.0 31.9 87.77 34.4 34.6 99.42 
101313 36.7 39.5 92.91 37.5 38.5 97.40 34.0 36.8 92.39 
101408 37.6 36.8 102.17 35.0 34.5 101.45 33.6 35.8 93.85 
101516 35.5 35.1 101.14 31.0 34.8 89.08 32.9 34.3 95.92 
101656 33.7 35.4 95.20 29.6 35.7 82.91 31.5 36.4 86.54 
101872 35.4 38.4 92.19 33.5 38.6 86.79 41.4 45.4 91.19 
101886 36.6 39.9 91.73 36.0 40.0 90.00 37.1 39.4 94.16 
102611 34.5 37.3 92.49 33.0 36.6 90.16 36.7 44.6 82.29 
103369 36.0 37.2 96.77 34.0 34.9 97.42 38.9 41.6 93.51 
103480 37.4 37.6 99.47 34.3 40.9 83.86 * *  
103521 37.1 37.5 98.93 33.9 40.2 84.33 34.4 41.9 82.10 
Mean + 
SD   
97.16 + 
5.45   
89.02 + 
5.25   
91.08 + 
4.77 
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Table 13: Peak vertical force (%BW) for dogs in the group C. preOP = 
preoperative day; OP1 = first postoperative day; OP2 = second postoperative 
day. Op = operated hind limb; nop = non operated hind limb.  
   preOP     OP1     OP2   
ID Op Nop op/nop% Op nop op/nop% op nop 
Op/nop
% 
94614 37.9 38.0 99.7 34.5 37.4 92.25 36.1 37.6 96.01 
100698 34.4 35.0 98.3 26.7 43.6 61.24 24.9 45.0 55.33 
96359 32.7 33.9 96.5 31.0 37.0 83.78 31.1 34.9 89.11 
101107 39.8 40.5 98.3 29.8 42.6 69.95 37.6 53.2 70.68 
101487 37.7 37.8 99.7 33.1 33.9 97.64 34.0 36.4 93.41 
101488 49.7 52.7 94.3 48.0 54.3 88.40 49.0 52.6 93.16 
101841 30.3 38.5 78.7 27.6 38.8 71.13 30.1 38.8 77.58 
101975 32.3 34.5 93.6 34.4 37.3 92.23 36.6 39.2 93.37 
102086 30.4 36.0 84.4 34.0 40.6 83.74 31.1 35.2 88.35 
102347 37.2 37.7 98.7 35.4 39.3 90.08 29.4 37.8 77.78 
102404 39.6 38.8 102.1 35.5 39.0 91.03 37.9 40.7 93.12 
102431 34.8 34.6 100.6 32.9 37.7 87.27 32.0 34.8 91.95 
103969 36.2 50.2 72.1 38.4 46.6 82.40 36.9 47.9 77.04 
102628 36.6 36.4 100.5 35.3 40.4 87.38 35.7 39.8 89.70 
91538 35.5 35.9 98.9 30.1 51.6 58.33 32.9 46.1 71.37 
95904 35.9 36.6 98.1 31.2 39.1 79.80 32.7 35.9 91.09 
Mean +  
SD     
94.66 + 
8.64     
82.29 + 
11.44     
84.31 + 
11.44 
 
Analyzing the data one can appreciate that the relation of the PVF of the operated 
limb to the non operated limb was similar before surgery between groups (p = 
0.31). On the first postoperative day the PVF of the operated leg decreased 
significantly compared to the non operated limb in both groups (p = 0.001 for 
both groups). On the second postoperative day a tendency of the calculated ratio 
to return to its preoperative value could be observed, but in both groups the ratio 
was still significantly lower than during the preoperative evaluation (p = 0.004 for 
both groups). However, the PVF ratio for dogs in group M was significantly 
higher than in group C on both postoperative days (p = 0.04) (figure 13, table 14). 
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Table 14: Mean values of PVF for dogs in the groups M and C.  
SD = standard deviation; p = significance level < 0.05  
 Group M Group C T test 
Day of examination Mean + SD Mean + SD P 
preOP 97.16 + 5.45 94.66 + 8.64 0.31 
OP1 89.02 + 5.25 82.29 + 11.44 0.04 
OP2 91.08 + 4.77 84.31 + 11.44 0.04 
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Figure 13: Peak vertical force ratio (op/nop%) of dogs in the groups M and 
C. 
* = statistically significant differences (p < 0.05). 
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2.2. Vertical impulse 
The vertical impulse (VI) of the hind limbs was measured and expressed in 
Newton per second (Ns). A relation between the values obtained for the operated 
hind limb and the non operated hind limb was calculated and expressed as a 
percentage (op/nop%). Data are shown in table 15 and16, 
 
Table 15: Vertical impulse (Ns) for dogs in the group M. preOP = 
preoperative day; OP1 = first postoperative day; OP2 = second postoperative 
day; op = operated hind limb; nop = non operated hind limb; * = patient 
refuse to walk. 
    preOP     OP1     OP2   
ID op Nop op/nop% Op nop op/nop% Op nop op/nop% 
95791 0.15 0.16 99.35 0.14 0.15 92.00 0.14 0.15 90.67 
98095 0.14 0.14 100.71 0.12 0.16 76.43 0.12 0.16 75.16 
96051 0.14 0.14 102.19 0.12 0.15 82.00 *   *   
99283 0.11 0.13 79.55 0.09 0.13 70.45 0.10 0.13 79.37 
99749 0.12 0.15 77.27 0.11 0.16 68.55 0.09 0.16 53.75 
100400 0.11 0.15 71.24 *  *    0.12 0.14 81.25 
100842 0.12 0.13 92.80 0.11 0.15 74.48 0.11 0.13 86.15 
101107 0.08 0.09 88.04 0.09 0.11 76.99 0.13 0.12 111.02 
101313 0.14 0.17 83.83 0.13 0.16 81.65 0.12 0.14 87.32 
101408 0.14 0.15 91.95 0.11 0.12 89.43 0.12 0.13 90.23 
101516 0.15 0.15 99.34 0.11 0.13 86.05 0.14 0.13 100.75 
101656 0.16 0.19 81.44 0.13 0.20 62.87 0.14 0.21 67.63 
101872 0.14 0.14 93.75 0.11 0.15 73.15 0.14 0.16 85.44 
101886 0.11 0.17 67.07 0.11 0.14 74.47 0.11 0.14 74.13 
102611 0.08 0.08 96.25 0.05 0.07 75.71 0.05 0.08 58.02 
103369 0.12 0.11 103.60 0.10 0.12 82.91 0.13 0.12 100.81 
103480 0.13 0.13 99.24 0.11 0.16 69,.81  * *    
103521 0.16 0.15 102.63 0.15 0.22 66.97 0.13 0,19 68.39 
Mean + SD     90.57 + 11.35     76.7 + 8.05     81.88 + 15.55 
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Table 16: Vertical impulse (Ns) for the dogs in the group C. preOP = 
preoperative day; OP1 = first postoperative day; OP2 = second postoperative 
day. Op = operated hind limb; nop = none operated hind limb.  
    preOP     OP1     OP2   
ID op Nop op/nop% Op nop op/nop% Op nop op/nop% 
94614 0.13 0.16 80.25 0.11 0.15 72.11 0.11 0.13 81.20 
100698 0.12 0.15 76.16 0.06 0.19 32.29 0.06 0.20 28.06 
96359 0.15 0.18 81.42 0.11 0.23 48.67 0.12 0.21 58.22 
101107 0.11 0.14 80.71 0.07 0.12 59.84 0.10 0.17 58.33 
101487 0.17 0.20 86.80 0.13 0.18 72.16 0.13 0.17 75.44 
101488 0.17 0.22 78.90 0.17 0.22 77.03 0.16 0.24 66.80 
101841 0.13 0.17 76.02 0.07 0.16 47.74 0.08 0.18 46.15 
101975 0.13 0.14 92.20 0.15 0.21 72.68 0.15 0.16 97.45 
102086 0.09 0.11 84.68 0.12 0.14 89.78 0.11 0.11 94.59 
102347 0.16 0.18 87.64 0.13 0.19 68.75 0.12 0.26 45.74 
102404 0.15 0.15 97.40 0.15 0.17 92.17 0.15 0.15 98.04 
102431 0.13 0.15 85.71 0.12 0.17 74.25 0.11 0.16 69.14 
103969 0.13 0.17 75.30 0.14 0.18 79.21 0.11 0.15 77.93 
102628 0.12 0.12 101.68 0.10 0.12 83.74 0.10 0.13 76.12 
91538 0.09 0.10 92.16 0.05 0.10 47.96 0.06 0.10 58.16 
95904 0.12 0.14 81.12 0.09 0.17 50.29 0.10 0.17 59.39 
Mean + SD     84.89 + 7.77      66.79 + 17.18     68.17 + 19.67 
 
Observing the data one can appreciate that the relation of the VI of the operated 
limb to the non-operated limb (op/nop%) before surgery was similar between 
groups (p = 0.1). On the first postoperative day the VI of the operated limb in both 
groups decreased significantly in relation to the non operated limb (p < 0.001 in 
group C and p = 0.02 in group M). On the second postoperative day VI values in 
group C showed a tendency to return to preoperative values, but were still 
significantly lower than preoperative values (p = 0.002). On the other side, VI 
values of dogs in group M showed no statistical differences on the second 
postoperative day compared to preoperative values (p = 0.09). Furthermore, the 
decrease of the vertical impulse for dogs in group M was lesser compared to that of 
dogs in group C on both postoperative days (p = 0.04) (figure 14, table 17). 
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Table 17: Mean values of the VI of dogs in the groups M and C. SD = 
standard deviation; p = significance level < 0.05 
 Group M Group C T test 
Day of examination Mean + SD Mean + SD P 
preOP 90.57 + 11.35 84.89 + 7.77 0.1 
OP1 76.7 + 8.05 66.79 + 17.18 0.04 
OP2 81.88 + 15.55 68.17 + 19.67 0.04 
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Figure 14: Vertical impulse ratio (op/nop%) of dogs in the groups M and C. 
* = statistical differences (p < 0.05). 
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VI. DISCUSSION 
Total hip replacement in dogs is a procedure that requires intraoperative pain 
management (RICHTER, 2007) and in spite of the surgeon’s care, tissue damage 
and cell destruction with the consequent liberation of inflammatory mediators of 
pain occurs (DRAY, 1995; LASCELLES et al., 1997). Increased knowledge, 
changing attitudes, and greater sensibility for animal welfare have increased the 
desire to treat pain in veterinary practice (MUIR et al., 2001). Additionally, an 
appropriate post-operative pain therapy with few or even no side effects has 
proven to result in a better and more satisfactory recovery (KEHLET and DAHL, 
1993). A lot of analgesic techniques have been applied both in humans as well as 
in veterinary medicine after orthopaedic surgery: those that include NSAIDS or 
opioids as sole analgesics and others that use a combination of several drugs to 
achieve superior pain relief (SINGELYN and GOUVERNNEUR, 1999; 
LAREDO et al., 2004; REMÉRAND et al., 2009). We decided to perform the 
study in dogs receiving a total hip replacement because this surgery is a well 
standardized procedure at our institution. Additionally, before the start of this 
research project we had the subjective impression that the sole use of a classical 
NSAID (e.g. carprofen) following THR in dogs often may not lead to sufficient 
analgesia. Therefore our aim was to find out whether postoperative analgesia 
might be superior with the use of metamizole. We decided to investigate the 
analgesic efficacy of sodium metamizole because of its recognized potency in 
human medicine and its few adverse effects compared to opioids (TORRES et al., 
2001; STRAMER et al., 2003). We compared metamizole’s efficacy with 
carprofen a recognized NSAID in veterinary medicine. Carprofen has 
demonstrated good pain relief after various types of surgeries in several clinical 
studies (NOLAN and REID, 1993; LASCELLES et al., 1994; LASCELLES et al., 
1998; GRISNEAUX et al., 1999; LAREDO et al., 2004; LEECE et al., 2005). All 
dogs were operated by the same surgeon and except for the postoperative 
analgesic regimen followed the same postoperative care. Based on the author’s 
knowledge, there are no studies on the clinical efficacy of metamizole after 
surgery in dogs.  
Mechanisms of pain have been profoundly studied, yet there is still an incomplete 
understanding of all the processes that finally lead to the conscious perception of 
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pain. A lot of anatomical structures and biochemical components participate and 
influence the four stages of nociception: transduction, transmission, modulation 
and perception (LAMONT, 2000; LEMKE, 2004). Therefore, the possibility that 
only one agent can completely block nociception is improbable. Due to this, it is 
common practice to combine different analgesics, and this approach has increased 
significantly over the last decade (ILKIW, 1999; GONZÁLEZ de MEJÍA, 2005; 
HELLYER, 2007). The complexity of pain physiology and thus the difficulty to 
standardize animals’ pain models makes experimental and clinical studies of 
different drugs very difficult and often leads to contradicting results (LAMONT, 
2000; LeBARS et al., 2001). In other words each species reacts differently to 
different stimuli and furthermore a psychological component may also be present 
(DEGENAAR 1979). Another factor that surely plays an important role is pain 
assessment. In clinical studies in humans the verbal expression of perceived pain 
allows a more reliable evaluation of analgesia, but with animals close observation 
and skilful interpretation of behavioural responses are essential for a satisfactory 
recognition of pain (HELLEBRECKERS, 2001; WATERMAN-PEARSON, 
2001). In our study we used the VAS, a scale approved in a lot of clinical studies 
both in human medicine as well in veterinary medicine (BRODBELT et al., 1997; 
DENEUCHE et al., 2004; SLINGSBY et al., 2006). To parameterize the 
behavioural data, we modified the Melbourne pain scale and we used it 
additionally to VAS to assess pain in dogs after total hip replacement.  The 
Melbourne pain scale has been successfully used in several clinical studies to 
evaluate pain and compare the efficacy of different NSAIDs like ketoprofen or 
carprofen and opioids like butorphanol after surgery (PIBAROT et al., 1997; 
HOLTON et al., 1998a; DENEUCHE et al., 2004; LAREDO et al., 2004; 
HOELZER et al 2005). To avoid interobserver variability (HOLTON et al., 
1998a) and to reduce bias, the study was blinded and just one observer performed 
the evaluations throughout the study. 
In this study the pain scales used gave good results. They were easy to use, did not 
require much time and were inexpensive. However, the physiological parameters 
heart rate and respiratory rate, sometimes failed to give information about the 
patient’s painful condition. Sixteen dogs (41 %), for example, panted at some 
point of the evaluations. Panting is common in dogs to ventilate dead space and to 
favour heat loss (ROBINSON 2003), but it is not necessarily an indicator of pain. 
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In panting dogs the respiratory rate was not considered for the evaluation. It 
seems, anyway, that respiratory rate and heart rate are good indicators of pain 
when patients are suffering severe pain. 
The subjective mMPS assessment contains a lameness examination (Appendix 1). 
However, it has been seen that subjective gait evaluation must be interpreted 
cautiously and often does not agree with objective measurements (WAXMAN et 
al. 2008). To obtain more objective results we subjected all patients to a gait 
analysis on an instrumented treadmill. This non-invasive analysis provides 
objective information about the degree of the lameness and therefore renders an 
indirect parameter of pain (BENNETT et al., 1996; EVANS et al., 2005). The gait 
analysis has proven useful in the diagnosis of lameness and related pathologies as 
well as in the confirmation of success after orthopaedic surgery in dogs 
(MANLEY et al., 1990; McLAUGHIN et al., 1991; KENNEDY et al., 2003). 
However, in this study, the pain scales showed greater differences between groups 
compare to the gait analysis. A reason for that may be that different dog breeds 
with different body weights and, more importantly, with different types of gait 
were used. This resulted in an enormous variability between patients. To reduce 
the variability, we decided to consider only the hind legs. Vertical impulse and 
peak vertical forces were measured and a ratio between the values of the operated 
limb and the non operated limb was calculated. It would be expected that a dog 
receiving sufficient analgesics would keep this ratio constant. This was not 
entirely the case in our study but it could be noted that dogs in the group C 
reduced their ratio much more than dogs in the group M, and these differences 
were significant.  Dogs receiving metamizole tended to distribute more weight on 
the operated limb than dogs in the group C. These results are an objective 
indicator that metamizole provided superior pain relief than carprofen in our 
study.  
According to the results of the pain scales metamizole showed better and more 
satisfactory analgesia compared to carprofen after total hip replacement. 
Carprofen is a well recommended NSAID for postoperative pain alleviation, yet 
in our study three patients (15%) that had received carprofen needed rescue 
analgesia because of excessive pain (VAS over 50 and mMPS over 12). However, 
the rest of the carprofen group seemed to be adequately treated and did not show 
any unwanted side effects to the therapy. Metamizole on the other side gave 
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satisfactory pain relief to all patients, and showed significantly lower pain scores 
after T3 for the mMPS and after T21 for VAS. However, it seems that acute 
postoperative treatment of pain was similar for both analgesics, because no 
statistical differences were seen during the first hours of the evaluation period. 
These results agree with findings in human medicine, where a single dose of 
metamizole in patients in moderate to severe postoperative acute pain supports 
good analgesia and is similar in efficacy compared to other analgesics like 
ibuprofen or diclofenac (REES et al., 2001; REES et al., 2002). However, other 
authors failed to find satisfactory results with metamizole when compared with 
other NSAIDs like meloxicam or diclofenac (CANDER et al., 2005; YILMAZ et 
al., 2006). As mentioned, carprofen is a well recognized analgesic to treat 
postoperative pain in dogs, especially if administered preemptively (NOLAN and 
REID, 1993; GRISNEUX et al., 1999; LASCELLES et al., 1998). It is therefore 
not surprising that there was no necessity for additional analgesia in 92.3% of the 
dogs. However, it is surprising that metamizole showed significantly better pain 
relief only after a couple of hours and not at the time of greatest postsurgical pain. 
Possible explanations for this fact include:  
(1) During the first nine hours of pain evaluation the patients were in the 
recovery phase of anaesthesia. The mean of anaesthesia was 281.4 
minutes, which most likely influences the following subjective pain 
evaluation. During the first six hours a lot of patients refused to stand up, 
maybe because of pain or maybe because they were simply still tired from 
their anaesthesia. Others may not have reacted to palpation of the wound 
because they were too tired to express their discomfort. The main problem 
is that pain scales in veterinary medicine lack sufficient accuracy 
(HOLTON et al., 1998a; HOLTON et al., 1998b) and may fail to detect 
some details that could make the difference between both groups in these 
extreme situations. This may lead to misinterpretation and inaccurate 
evaluation during the first postoperative hours.  
(2) Another fact that could play an important role is the time of drug 
application. Carprofen was administered intravenously preoperatively, 
which means that once the surgeon began to operate, carprofen was 
already exerting an effect (DAHL et al., 1990; WOOLF et al., 1993). 
Metamizole on the other hand was given intravenously once the surgery 
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was finished. The patients receiving metamizole did not get any analgesic 
that blocked the production of inflammatory mediators (DRAY, 1995) and 
underwent the surgery with fentanyl as the only analgesic drug. This 
situation may have resulted in an advantage for the carprofen group during 
the first postoperative hours, because in the metamizole group there was 
no drug to decrease the intraoperative production and liberation of 
biochemical mediators. Despite of this the metamizole group showed 
satisfactory analgesia the whole study period,  
(3) Another explanation of this phenomenon in the first postoperative hours 
may be that total hip replacement is a severely painful process 
(TRANQUILLI, 1997) that would need very potent analgesics during the 
first hours after surgery to see complete pain relief (KEHLET AND 
DAHL, 1993). In the early postoperative phase the endogenous 
mechanisms of pain control may not have been fully activated and the sole 
use of NSAIDs during this period may be of limited benefit. After a few 
hours the brainstem and its central control of pain become active, 
supporting the action of the analgesics present (MILLAN, 2002; MELLO 
AND DICKENSON, 2008). Metamizole may be potentiated by this 
mechanism to a greater extend than carprofen resulting in significant 
differences between groups after 21 (9) hours.  
(4) Metamizole possesses an antihyperalgesic activity, probably through a 
modulatory effect on the central mechanism of pain control. This 
antihyperalgesic activity may be related to the ability of metamizole to 
inhibit mechanical nociception in spinal dorsal horn WDR neurons 
(VAZQUEZ et al., 1995). As mentioned earlier, WDR neurons, once they 
are sensitized, react to any stimulus and produce chronic central pain 
(DUBNER, 1990; ZHANG et al., 2005). Another characteristic that plays 
an important role in the prevention of hyperalgesic states is the blockade 
of NMDA receptors (WOOLF and THOMPSON, 1991). The study of 
BEIRITH et al. (1998) suggests that metamizole seems to have the ability 
to modulate excitatory amino acid release at the spinal cord, and a direct 
interaction with the binding of glutamate on its receptors may be part of 
the antihyperalgesic action of metamizole. 
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Metamizole did not exhibit significantly better results at all time points, but it 
showed a clear tendency towards a better outcome in all the patients evaluated. 
Research studies clearly show that the mechanism of action of metamizole is 
distinct from that of the “classical” NSAIDs. Since the exact mechanism of action 
of metamizole is still unclear, the explanations of its better analgesic action may 
be intriguing. Some authors postulate a strong PG inhibitory effect at central and 
peripheral levels, and others suggest a direct action in the PAG involving the 
opioidergic system and the central descending control of pain (LORENZETTI and 
FERREIRA, 1985; TORTORICI and VANEGAS, 1993; 
CHANDRASEKHARAN et al., 2002). One of the most mentioned and most 
discussed mechanism is the activation of the L-arginine/NO/cGMP pathway with 
the subsequent increased production of NO (LORENZETTI and FERREIRA, 
1996; ALVES and DUARTE, 2002). The activation of the L-arginine-NO-cGMP 
pathway with resulting antinociception has been documented (DESOKY and 
FOUAD, 2005). There is, both in the periphery as well as in the CNS, a direct 
relationship between acute hypernociception blockade and the stimulation of the 
L-arginine-NO-cGMP pathway (KNOWLES et al., 1989; DUARTE et al., 1992; 
SACHS et al., 2003). However, the role of NO in nociception seems to be 
paradoxical, since the application of L-NAME (NOS inhibitor) leads to a 
decreased nociceptive response in rats (BUDAI et al., 1995) and farther, the 
intrathecal injection of NO-donating compounds like sodium nitroprusside (SNP) 
resulted in hyperalgesia in mice (KITTO et al., 1992). These findings do not agree 
with that of LORENZETTI and FERREIRA (1985) where the application of L-
NAME reverted the analgesic effects of metamizole and given alone provoked 
hyperalgesia, suggesting that NO may have a participation in the antinociceptive 
activity of metamizole.  BEIRITH et al. (1998) refuse this theory since in their 
experiments the application of NO inhibitors to mice did not influence the 
antinociceptive action of metamizole. As mentioned, NO seems to act both 
pronociceptive as well as antinociceptive, depending on the experimental model 
used to induce nociception as well as the route of drug administration. In humans 
it was demonstrated that NO acts pronociceptive when it is intracutaneously 
injected (HOLTHUSEN and ARNDT, 1994). In contrast, one study of 
IWAMOTO and MARION (1994) approved the hypothesis that the 
antinociception produced by muscarinic stimulation of the RVM is mediated by 
the L-arginine/NO/cGMP cascade. There is also evidence that NO mediates the 
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peripheral antinociceptive effect of some potent opioids like fentanyl or morphine 
(SONG et al., 1998; MAEGAWA and TONUSSI, 2003). All of these findings 
indicate that the L-arginine/NO/cGMP pathway is unlikely neither the only nor a 
direct mechanism of metamizole’s analgesic action. However, one cannot deny 
that NO may at least partly mediate the antinociceptive activity of this drug.  
The fact that metamizole modulates the excitatory amino acid release and that its 
antinociceptive properties depend on the NMDA receptors blockade, makes the L-
arginine/NO/cGMP pathway more doubtful. Findings in slices of rat hippocampus 
suggest that NMDA receptor activation induces the generation of NO from 
arginine and mediates the increases in cGMP levels (EAST and GARTHWAITE, 
1991). Furthermore the intrathecal injection of glutamate in mice produces 
hyperalgesia and this is largely mediated by the L-arginine-nitric oxide-cGMP 
pathway from both supraspinal and spinal sites (FERREIRA et al., 1999). 
Moreover in a study of MAURA et al. (2000) hyperalgesia produced by NMDA 
receptor agonists was blocked with the application of a NO synthase inhibitor Ng-
nitro-L-arginine (L-NOARG). NO production appears to mediate NMDA-induced 
hyperalgesia and may contribute to other forms of centrally induced 
hypersensitivity (KITTO et al., 1992). From this it is difficult to relate the 
analgesic action of metamizole with NO production, especially if its 
antinociception may involve a direct interaction with glutamate receptors. 
Recently, findings of SIEBEL et al. (2004) further support the previous 
hypothesis that the antinociception caused by metamizole is associated with its 
interaction with the glutamatergic system, more specifically via interaction with 
the metabotropic glutamatergic system. In addition, they suggest a direct or 
indirect interaction of metamizole with a NK1-mediated pathway and with PKC-
dependent mechanism. NK1 receptors are mostly distributed in Lamina I 
(MORRIS et al., 2004). In the superficial layer of the dorsal horn C- and A-fibres 
are inhibited by the descending control of the PAG (KOUTSILOU et al., 2007). 
This could explain why metamizole has the capacity to inhibit both somatic and 
visceral pain as well as first and second pain.     
As mentioned before, the PAG and RVM are recognized as the central sites of 
action of analgesic agents like opioids and cyclooxygenase inhibitors (LEITH et 
al., 2007). The response to noxious stimuli can be further influenced by the 
recruitment of RVM ON-cells and OFF-cells. Nociceptive threshold is lowest 
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when the ON-cells population is active and OFF-cells are silent (HEINRICHER et 
al., 2009). Glutamatergic transmission blockade, and presumably blockade of ON-
cells responses results in disfacilitation and thus reduction of the magnitude of 
noxious stimulus-elicited responses (JINKS, 2007). One consequence of these 
modulations is that the relationship between stimulus and response to pain is not 
always directly proportional. The response of output cells can be greatly altered 
via the interactions of various neurotransmitter systems in the spinal cord, all of 
which are subject to plasticity and alterations, particularly during pathological 
conditions (MELLO and DICKENSON, 2008). Pathological conditions may 
induce significant changes in the function of descending pain-modulatory 
pathways leading to facilitation or attenuation of nociception (VANEGAS and 
SCHAIBLE, 2004). As total hip replacement is an indication of coxarthrosis in 
dogs (MATIS, 1995) all patients involved in this study suffered from chronic 
painful arthritis. In one study of PINTO-RIBEIRO et al. (2008), rats with arthritis 
presented partly a different neurochemistry of descending antinociception 
compared to the control group, and the spontaneous activity of both 
pronociceptive ON-cells and antinociceptive OFF-cells was increased in arthritic 
rats. These findings could explain why patients respond differently to each 
analgesic therapy. In our study we saw that patients that received carprofen 
showed completely different behavioural responses. Some patients showed 
satisfaction and no pain with 4 mg kg-1 carprofen a day, while others seemed 
painful and it was necessary to treat them with rescue analgesia (3/20). 
Interestingly, all patients receiving metamizole showed a low variability in their 
pain scores. All of them presented low pain scores and therefore satisfactory pain 
relief. This may be due to a stronger activity of metamizole at central levels and 
its potential effects on medullary OFF- and ON-cells (TORTORICI and 
VANEGAS, 1993; TORTORICI et al., 1996). Carprofen as a COX-inhibitor 
reduces the PG production in the periphery (CURRY and COOK, 2005) and 
exerts spinal modulation through the COX-prostaglandin pathway in the PAG, 
which is also the target of µ-opioid analgesics (LEITH, 2007). However, there is 
no evidence of carprofen’s effect on ON- or OFF-cells in the RVM. Because there 
is clinical evidence of synergic actions of NSAIDs and opioids (HELLYER, 1999; 
PIBAROT et al., 1997), presumably carprofen would have produced a better 
analgesia when combined with opioids.  
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Some patients presented unwanted side effects in this study: six dogs had 
diarrhoea; one of them belonged to the carprofen group and the rest to the 
metamizole group. Three dogs vomited and all of them were from the metamizole 
group. It seems like carprofen as a COX-2 inhibitor might be associated with less 
gastrointestinal side effects and discomfort than metamizole. Despite not being a 
potent COX-inhibitor, metamizole may produce stomach discomfort (nausea) 
(REES et al., 2001; REES et al., 2002). However, because of its gastrointestinal 
safety other authors recommend the use of metamizole in human patients where 
NSAIDs are contraindicated (BIANCHI et al., 1996). Metamizole does not 
produce GI ulcers and may even promote GI mucous blood flow (ERGÜN et al., 
2001). Carprofen, on the other side, is a safe drug for chronic therapy in dogs 
(MANSA et al., 2007), but cases of GI ulcers produced by COX-2-inhibitors have 
been reported and care has to be taken when these drugs are chronically 
administered (LASCELLES et al., 2005; TERRENCE, 2006). Possibly the dose of 
metamizole used in this study – although recommended by the manufacturer - 
may provoke the described gastrointestinal side effects. More studies are 
warranted to evaluate the gastrointestinal safety of metamizole in this species.  
 
Regardless of its mechanism of action, in our study the sole use of metamizole 
(50mg/kg) three times daily granted a satisfactory analgesia and clearly performed 
better than carprofen in all the evaluations made (pain scales and gait analysis) 
after total hip replacement in dogs. These results suggest that at the recommended 
dose, metamizole is a potent and satisfactory analgesic drug for use after 
orthopaedic surgery in dogs. The administration of 4 mg·kg-1 of carprofen as the 
sole analgesic after THR in dogs may not be sufficient in some patients. The 
possibility to combine NSAIDs like carprofen with non opioid analgesics like 
metamizole may be a good and safe alternative to treat both intra- as well as 
postoperative pain in dogs and this may serve especially useful in countries where 
opioids are not licensed in veterinary medicine. More studies will have to be 
performed to evaluate the efficacy and safety of this drug combination.  
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VII. ZUSAMMENFASSUNG 
Evaluierung von Metamizol und Carprofen als postoperative Analgetika 
nach Hüftgelenksersatz bei Hunden. 
 
Das Ziel dieser Studie war es, die analgetische Wirkung der von den jeweiligen 
Arzneimittelfirmen für den Hund empfohlenen Dosierungen von Metamizol im 
Vergleich zu Carprofen nach Hüftgelenkersatz zu bewerten. Es ist bekannt, dass 
Metamizol ein potentes Analgetikum beim Menschen ist. Bis heute gibt es keine 
Studien zur postoperativen Wirksamkeit von Metamizol beim Hund. Subjektive 
(Melbourne Schmerzskala (mMPS) und visuelle Analogskala (VAS)) und 
objektive (Ganganalyse, in welcher die vertikale Spitzenkraft (PVF) und der 
vertikale Impuls gemessen wurden) Bewertungsverfahren wurden in dieser Studie 
für die Evaluierung der Schmerzen herangezogen.  
39 klinisch gesunde Hunde mit einem Körpergewicht zwischen 5,5 und 60,5 kg 
(keine Rassespezifität) wurden in diese Studie eingeschlossen. Die Hunde wurden 
nach Randomisierung in zwei Gruppen verteilt: Tiere der Gruppe M (n = 19) 
erhielten 50 mg·kg-1 IV Metamizol TID. Tiere der Gruppe C (n = 20) erhielten 4 
mg·kg-1 Carprofen IV SID. Die Patienten wurden 3, 6, 9, 12, 20, 24, 28, 32, 36, 
44, 48 and 56 Stunden nach Operationsende subjektiv beurteilt. Wurden bei der 
Evaluierung mittels mMPS bzw. VAS Punktwerte von 12 bzw. 50 Punkten 
überschritten, so wurde dies als Anzeichen von Schmerzen betrachtet, welche mit 
einer intravenösen Gabe von Buprenorphin, 10 µg·kg-1, behandelt wurden (rescue 
analgesia). Eine Ganganalyse wurde einmal präoperativ (preOP) und dann am 
ersten (OP1) und zweiten (OP2) postoperativen Tag durchgeführt.  
Drei Patienten in der Gruppe C benötigten in den ersten 3 bis 6 postoperativen 
Stunden rescue analgesia. Keines der Tiere in Gruppe M benötigte die Gabe 
zusätzlicher Schmerzmittel. Sowohl bei der mMPS als auch bei der VAS zeigten 
Tiere der Gruppe M im Vergleich zu Gruppe C über den gesamten Zeitraum 
niedrigere Schmerz-Werte. Je nach verwendeter Schmerzskala waren diese 
Unterschiede nach 6 h (mMPS) bzw. nach 24 h (VAS) als signifikant zu 
betrachten (p < 0.05). Die postoperativen Ganganalysen zeigten bei Hunden der 
Gruppe M eine bessere Belastung der operierten Gliedmaße (p < 0.05).  
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Diese Ergebnisse zeigen, dass die alleinige Verwendung von Metamizol als 
Analgetikum eine potente und zufriedenstellende Analgesie nach orthopädischen 
Eingriffen bei Hunden gewährleistet. Des Weiteren wurde gezeigt, dass die 
alleinige Verwendung von Carprofen in der vom Hersteller empfohlenen 
Dosierung nach Hüftgelenksersatz bei Hunden nicht immer eine 
zufriedenstellende Analgesie hervorruft. 
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VIII. SUMMARY 
Evaluation of Metamizole and Carprofen as postoperative analgesics in 
canine total hip replacement 
 
The aim of this study was to evaluate the analgesic action of sodium metamizole 
compared to that of carprofen after THR in dogs at dosages recommended by their 
respective manufacturers. Metamizole is a potent analgesic in humans and until 
now there are no studies on its postoperative efficacy in dogs. In this study, 
multiple evaluation methods were used for pain assessment: two subjective pain 
scales, the modified Melbourne pain scale (mMPS) and the visual analogue scale 
(VAS). For objective assessment dogs were subjected to a gait analysis where 
peak vertical force (PVF) and vertical impulse (VI) were measured. 39 clinically 
healthy dogs weighing between 5.5 and 60.5 kg (no breed specificity) were 
enrolled in this study. Dogs were randomly distributed to two groups: dogs in 
group M (n = 19) received 50 mg·kg-1 IV metamizole TID and dogs in group C (n 
= 20) received carprofen (4 mg·kg-1 IV) SID. Dogs were subjectively evaluated 3, 
6, 9, 12, 20, 24, 28, 32, 36, 44, 48 and 56 hours after the end of surgery. Dogs that 
scored more than 12 points on the mMPS or more than 50 points on the VAS were 
considered to be suffering from pain and received rescue analgesia (10 µg·kg-1 
buprenorphine IV). Gait analysis was performed once preoperatively (preOP) and 
on the first (OP1) and second (OP2) postoperative day. 
Three patients in group C needed rescue analgesia during the first 3 to 6 
postoperative hours. Patients in group M did not need any additional analgesia. 
Modified MPS and VAS showed lower pain scores in group M compared to group 
C during the whole evaluation period. Depending on the pain scale used these 
differences became significant after 6 h (mMPS) or 24 h (VAS) (p < 0.05). Gait 
analysis revealed better loading of the operated leg for dogs in group M on both 
postoperative days (p < 0.05). 
These results suggest that metamizole used alone is a potent analgesic drug which 
conveys satisfactory analgesia after orthopaedic surgery in dogs. On the other 
hand, at the dose recommended by the manufacturer carprofen does not always 
provide sufficient analgesia after THR in dogs.  
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